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Cardiovascular diseases, including acute myocardial infarction, stroke, 
peripheral arterial diseases, and pulmonary embolism, are the most common and 
growing cause of morbidity and mortality in the United States. Early reperfusion of 
occluded blood vessels can be achieved by using thrombolytic therapy. However, 
thrombolysis is associated with its side effects, including bleeding complications and 
reocclusion. The hours after treatment for myocardial infarction represent a critical 
period when the patient is subject to reocclusion and a second coronary event. While 
rapid release on the order of minutes is desirable initially, an extended half-life of a 
thrombolytic agent functions better to address reocclusion.  
The overall goal of this research was the design, synthesis, characterization and 
testing of microspheres which i) are suitable for extension the half-life of a thrombolytic 
agent for prevention of reocclusion in vitro, and ii) provide a general controlled release 
by triggered release mechanism for cardiovascular delivery of therapeutic drugs.  
The first project of this thesis is to synthesize dextran acetate (DA) with various 
degrees of substitutions (DA1<DA2<DA3) and prepare, characterize polyethylene 
glycol (PEG)/DA microspheres which were combined with PEG microspheres to 
provide short and intermediate term release. Bovine serum albumin (BSA) was used as 
a model protein. PEG/DA3 microspheres exhibited the release of BSA on the scale of 
hours (180 min), more slowly than that of PEG microspheres. The percentage of BSA 
released from PEG and PEG/DA3 microspheres with time (min) was modeled 
mathematically [YPEG = 100(1 – e
−0.12t
); YPEG/DA3 = 100(1 – e
−0.024t
)] in order to predict 
xv 
cumulative delivery from mixtures in vitro over a period of hours when constrained to a 
target level at 30 min.  The system is examined for potential application in thrombolytic 
therapy. 
The second project is to develop and characterize eudragit (Eud) microspheres 
which were coated with chitosan (CS) by the covalent bonding in order to meet short 
and longer term needs. The extension of thrombolytic activity of these microspheres in 
in vitro experiments was also examined. CS-Eud/SK microspheres had a lower 
encapsulation efficiency of streptokinase (SK), reduced activity of SK, and a much 
slower release of SK when compared with those of Eud/SK microspheres. Release of 
SK from Eud/SK microspheres obeyed first-order kinetics model [YEud/SK = 100(1 – 
e
−0.6t
)] while release of SK from CS-Eud/SK microspheres obeyed the Hixson-Crowell 
model [YCS-Eud/SK = 100(1 – (1 – 0.1t)
3
)]. Counter-intuitively, slower release leads to 
faster thrombolysis as a result of greater penetration of agent into the thrombus and the 
mechanism of distributed intraclot thrombolysis. In the in vitro lysis experiment, the 
presence of CS coating on the surface of Eud/SK microspheres induced a much slower 
release of SK up to 8 h which would seem to provide clot-lytic efficacy in prevention of 
second blockage up to 4 h. This study has demonstrated that longer release times 
leading to extended half-life in plasma can be expected to offer prevention of 
reocclusion.  
The third project is to synthesize and characterize a novel amine-modified 
acetalated dextran polymer which is combined with heparin to develop triggered release 
microspheres for the delivery of therapeutic agents. In this study, we extend the 
underlying concept of Yang's ATTEMPTS (antibody targeted, [protamine] triggered, 
xvi 
electrically modified prodrug-type strategy) system to enable controlled release from 
microspheres. By encapsulating a drug in a cationic dextran-heparin microsphere, we 
broaden the protamine initiated release mechanism so that delivery can be generalized 
to a greater range of agents. In particular, a drug need not be electrically modified with 
this approach. 
1 





In the United States, cardiovascular diseases are estimated to account for greater 
than 32% of all deaths annually, in which myocardial infarction and ischemic stroke are 
considered the most severe cases of thrombosis (1). The formation of an occlusive 
thrombus in an artery has been identified as a leading cause of common cardiovascular 
diseases. To decrease the incidence of morbidity and increase patient survival, early 
detection and using thrombolytic therapy are necessary. Thrombolytic therapy with the 
administration of a plasminogen activator (PA) or a so-called “clot-busting” drug breaks 
up the clot and restores flow with proven efficacy in saving lives and reducing 
morbidity (2). Multiple PAs [tissue-type plasminogen activator (tPA), streptokinase 
(SK), urokinase] are available and being used in clinical practice. PAs activate the 
proenzyme plasminogen to plasmin, which can lyse a solid fibrin clot, resulting in  
clearing the occluded blood vessel and allowing the blood flow to be re-established (3, 
4).  
Despite the benefit of fibrinolysis achieved with PAs, thrombolytic therapy has 
some limitations, including high risk of bleeding complications and reocclusion (5). 
Intracerebral hemorrhages occur in approximately 1% of patients treated for acute 
myocardial infarction (6) and in 7% of those treated for stroke by thrombolysis agents 
(5). Reocclusion of coronary arteries after reperfusion occurs in 7-32% of patients (7) 
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and associates with the increase the level of infarct and mortality (8). The mechanism of 
reocclusion is not well understood, but it may be induced by several factors including 
thrombi traveling downstream, the release of various chemicals that cause restenosis 
due to spasm of the blood vessel or the exposure of active surface that initiates platelet 
response (9). Reocclusion after thrombolysis associates with the residual thrombus 
because the surface of the residual thrombus is highly thrombogenic (10, 11). 
Moreover, it has been noticed that reocclusion occurs inversely to the plasma half-life 
of the thrombolytic agent used (12). Therefore, maintenance infusion of PAs after 
thrombolysis for prolonging the half-life of PAs was used to prevent coronary artery 
reocclusion (13, 14). However, due to high risk of bleeding (15), this method has not 
gained wide acceptance. It is therefore reasonable to infuse of PAs in delivery vehicles 
that protect them from enzymes and antibodies in the circulatory system in order to 
prolong drug retention for prevention of reocclusion.  
Encapsulation PAs in liposomes, microspheres, and nanospheres shows great 
promise in improving the performance of PAs by accelerating thrombolysis and 
reducing bleeding complications (9, 16, 17). The greater advantages of encapsulation 
have been achieved when drug vehicles have been targeted to thrombi by attaching 
ligands, e.g. RGD (Arg-Gly-Asp) peptides, to their surfaces (18, 19) or by using 
magnetic devices (20, 21). Encapsulation also extents the half-life of PAs and maintain 
the drug activity for long-term effects (19, 22). Therefore, encapsulation shows some 
promise in addressing reocclusion but few studies have been conducted using 
encapsulated PA for reducing the rate of reocclusion. For these reasons, this study has 
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focused towards the development of formulations of encapsulated PA that provide 
benefit in prevention of reocclusion. 
The purpose of this research is to develop formulations that would not only 
restore blood flow rapidly, but also would act to prevent formation of secondary 
thrombus. Our group has shown that polyethylene glycol (PEG) microspheres provide 
the release of the encapsulated SK on the scale of minutes, which dissolves blood clots 
more quickly by enabling the penetration of SK into the interior of the clot with faster 
digestion (9, 23). We aim to prepare microspheres which exhibit the release of active 
agent on the scale of hours. These microspheres can be used with PEG microspheres to 
provide complementary action with delayed release to prevent a putative second 
thrombus. To reach this stage, we first need to synthesize the polymer that facilitates the 
release of thrombolytic agent within hours in order to address reocclusion. Then, we 
characterize the ability of the polymer and microspheres for that purpose. 
In another approach for producing the effective thrombolysis and reducing 
bleeding complication, Yang et al. have pioneered the ATTEMPTS (antibody targeted, 
triggered, electrically modified prodrug strategy) concept for targeted and triggered 
delivery of thrombolytics (24-26). In this approach, cation-modified tPA was attached 
to a heparin-antifibrin complex via ionic attraction. Protamine, a competitive heparin 
inhibitor, was used as a triggering agent to release the active tPA from the prodrug for 
clot dissolution. In this study, we extend the underlying concept of Yang's ATTEMPTS 
system to enable an on-demand controlled release from microspheres that might 
enhance therapeutic efficacy and reduce systemic side effects of thrombolysis. 
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In the light of the above-mentioned aspects, the objectives of our research 
project were threefold:  
1) To synthesize and characterize dextran acetate (DA), prepare and characterize 
PEG/DA microspheres which were combined with PEG microspheres to provide short 
and intermediate term release. 
2) To develop and characterize the covalent linking of chitosan to eudragit/SK 
microspheres to meet short and longer term needs. The extension of thrombolytic 
activity of these microspheres in in vitro experiments was also examined. 
3) To synthesize and characterize a novel amine-modified acetalated dextran 
polymer which are combined with heparin to develop triggered release microspheres for 
cardiovascular delivery of therapeutic agents. 
Chapter 2 gives a detailed background and the biological processes related to 
thrombosis, thrombolysis and reocclusion, and the development of encapsulation of PAs 
in order to better understand the pathogenesis and prevention of reocclusion. Chapter 3 
describes the synthesis of DA and the characterization of DA/PEG microspheres. 
Chapter 4 presents the development of delayed release chitosan-eudragit/SK 
microspheres and describes in vitro thrombolytic experiment for prevention of a 
putative second thrombus. Chapter 5 describes the synthesis of a novel amine-modified 
acetalated dextran polymer for the preparation of triggered release microspheres. 
Finally, Chapter 6 includes an overall summary and suggests important areas of further 













Vascular thrombosis is a major event in the pathogenesis of ischemic conditions 
including myocardial infarction, stroke, venous thromboembolism (deep vein 
thrombosis), pulmonary embolism , and other vascular obstructions (27). Thrombosis is 
the most common and growing cause of morbidity and mortality in the United States. 
Most cases of myocardial infarction and of about 80% of strokes are caused by acute 
arterial thrombosis (28) which lead to the death rates of myocardial infarction and 
stroke between 10-20%, and 20-50%, respectively (1) Deep vein thrombosis and 
pulmonary embolism are the third leading cause of cardiovascular-associated death, 
after myocardial infarction and stroke (28). 
Thrombosis is the pathological presence of a thrombus in the circulation. When 
an injury occurs at a blood vessel, platelets and fibrin form an immediate thrombus to 
prevent bleeding (29). Although this process is a protective response to cardiovascular 
injury to halt bleeding, the unnecessary changes that occur in the blood vessel wall and 
in the blood itself result in thrombosis: alteration in vessel wall, alteration in blood flow, 
and alteration in blood constituents (30). These three categories of thrombosis are 
known as Virchow’s triad (31). However, clot formation is thus a more complex 
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interplay between the three criteria of Virchow’s triad rather than a simple occurrence 
of one condition. 
Under normal condition, intact vascular endothelium acts as a barrier for 
limiting the access and permeability of procoagulant proteins to the procoagulant 
surfaces that lie beneath it, thus helping to maintain patency of blood vessels. Moreover, 
the endothelial cells provide antithrombotic substances which defend against thrombus 
formation, including nitric oxide (NO) that regulate vasodilation and antiplatelet 
activities (32), endothelin-1 (ET-1) that is a potent vasoconstrictor (33), and a 
prostaglandin (PGI2) with the most potent endogenous inhibitor of platelet aggregation 
(34). Vascular endothelium injury can occur as a result of multiple factors such as 
smoking, hypertension, hypercholesterolemia, and hyperlipidemia (30). Damaged 
endothelium exposes the underlying collagen and tissue factor to flowing blood. 
Exposed collagen triggers the accumulation and activation of platelets, whereas exposed 
tissue factor initiates the generation of thrombin, which not only converts fibrinogen to 
fibrin but also activates platelets, initiating formation of a thrombus (29). 
The second portion of Virchow’s triad is abnormal forms of blood flow which 
include turbulence and stasis (31). Turbulence can arise from specific regions such as 
vessel branches, bifurcation and curvatures or from pathological atherosclerotic plaques 
and blood hyperviscosity. When blood flow moves from laminar flow to turbulent flow, 
countercurrents and local pockets of stasis can occur. Stasis is a major factor in the 
development of thrombi and can arise from several sources. For example, irregular 
contraction due to atrial fibrillation or a faulty valve can reduce the cardiac ejection 
fraction, causing the blood that is not ejected to pool, creating a thrombogenic 
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environment. In addition, a non-contractile myocardium following infarction can lead to 
formation of a mural thrombus. Blood can also become trapped in an aneurysm or 
remain stagnant downstream of an occluded vessel. When blood is no longer in 
circulation and becomes static, thrombi are prone to form. 
The last portion of Virchow’s triad, abnormal blood constituents, refers to 
abnormalities in platelets, as well as coagulation and fibrinolytic pathways. 
Cardiovascular risk factors, including smoking, hypertension and diabetes mellitus 
cause chronic endothelial cell injury, resulting in increased platelet adhesion to the 
endothelium (30). Acute endothelial injury or rupture of a complicated plaque leads to 
exposure of the sub-endothelium and binding of platelets via sub-endothelial bound von 
Willebrand factor (vWF) thus potentiating thrombosis. Altered shear stress states also 
induce platelet activation, aggregation and microparticle formation, further potentiating 
thrombogenesis (35). 
Thrombosis may cause vascular blockage, leading to a lack of blood or oxygen 
supply to the organs in the body. Depending on the site of thrombus and the extent of its 
growth to occupy the cross-section of a blood vessel, thrombotic events can cause tissue 
death, dysfunction of the organs and possible death. A number of cardiovascular 
diseases are the direct results of vascular thrombosis: myocardial infarction, stroke, 
deep vein thrombosis, pulmonary embolism. However, the pathophysiology of arterial 
thrombosis differs from that of venous thrombosis (28). 
Arterial thrombosis is typically associated with atherosclerotic plaque rupture 
(36, 37). This pathogenic process results in exposure or release of subendothelial cells 
and procoagulant material such as tissue factor, collagen from within the plaque and 
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activation and aggregation of platelets (Figure 2.1). The growing thrombus increases the 
degree of stenosis which can result in extremely high shear rates (up to 70,000 s
-1
) 
within the stenotic region (38). In some cases, depending on stenosis geometry and 
location in the blood vessel, turbulent flow may develop downstream of the stenosis. 
Ultimately, platelet accumulation and fibrin deposition produces an occlusive platelet-
rich intravascular thrombus (28, 31)  
 
 
Figure 2.1. The Development of Arterial Thrombosis (31). 
 
In contrast, venous thrombosis is typically associated with plasma 
hypercoagulability and thought to be triggered by expression of procoagulant activity 
on intact endothelium from inflammation and/or low blood flow and shear stress 
resulting from prolonged immobility (Figure 2.2). Venous clots have regions or layers 
showing substantial erythrocyte incorporation or “red thrombi” (28, 31, 39). 
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Figure 2.2. The Development of Venous Thrombosis (31). 
 
Understanding the interplay between the components of Virchow’s triad and its 
associated disorders will allow us to design more effective and safe therapeutics to treat 
thrombotic events.  
2.2. Thrombosis treatment 
The general methods of treatment for cardiovascular thrombosis involve 
administering anticoagulant drugs or thrombolytic agents, percutaneous transluminal 
coronary angioplasty, and bypass graft surgery depending on the location and size of 
thrombus, time of occlusion. Many of these factors must be weighed before determining 
the use of thrombolytic agents or surgical interventions.  
Anticoagulants such as heparin and coumarin derivatives are mainstays in 
prevention and treatment of arterial or venous thrombosis where rapid clot dissolution is 
not necessary, including prevention of venous thromboembolism and long-term 
prevention of ischemic stroke in patients with atrial fibrillation (28, 40). However, these 
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drugs have the problem of increasing the risk of bleeding during their administration 
(41).  
Both invasive techniques such as angioplasty and bypass graft surgery require 
personnel with expertise, equipment and might not be life-saving, where time is an 
important factor, as most of the deaths due to thrombosis occur within the first 6 hours 
of attack. 
Thrombolytic therapy use activators of the fibrinolytic system, namely ‘clot 
busters”, to degrade fibrin, which stabilizes the structure of a thrombus (3). The success 
of thrombolysis depends crucially on the timing of intervention, with earlier 
intervention generally having a better outcome. For example, fibrinolytic therapy seems 
to be beneficial for at least 12 hours after the onset of symptoms of acute myocardial 
infarction and proven beneficial only when used within 3 hours for stroke. Therefore, 
thrombolytic therapy has the advantage that they are quicker, inexpensive method and 
can reach a large population. 
2.2.1. Thrombolysis 
Thrombolytic therapy uses plasminogen activators (PAs) such as tissue type 
plasminogen activator (tPA), streptokinase (SK), staphylokinase, urokinase and their 
derivatives to degrade the fibrin network that provides the structure of the thrombus and 
dissolve the clot (2, 3). PAs initiate a cascade of events that result in the dissolution of 
the blood clot and the recanalization of the blood vessel. PAs converse inactive blood 
plasminogen to its active form of plasmin, upon which plasmin degrades fibrin network 
into soluble fibrin degradation (Figure 2.3). The systemic plasmin is rapidly inactivated 
by α2-antiplasmin, but, by contrast, the plasmin generated at the fibrin surface is 
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protected from neutralization of α2-antiplasmin and thus localizes the action of 
fibrinolysis only on the fibrin clot. The free activators in the plasma are regulated by 
plasminogen activator inhibitor (PAI-1) (3, 4). The available thrombolytic agents are 








The activation mechanism and the affinity of thrombolytic agents towards 
plasminogen in the presence or absence of fibrin are different. Based on the activation 
mechanism, PAs are classified into the direct and indirect activators. tPA and its 
variants, urokinase are direct activators which convert plasminogen to plasmin directly. 
By contrast, SK and staphylokinase are indirect activators. They must first combine 
with plasminogen to form a 1:1 molar ratio activator-plasminogen complex, which then 
becomes the activators. 
In term of their affinity to fibrin, the activators are divided into two groups (37): 
fibrin-specific plasminogen activators, including tPA, recombinant single chain 
urokinase, and staphylokinase; and nonfibrin-specific activators which comprise two 
chain urokinase, SK, and acylated plasminogen streptokinase activator complex 
(APSAC). 
Despite of its achievements, thrombolytic therapy has several limitations. 
Thrombolytic drugs are rapidly inactivated by PAI-1 and antibodies in the circulation. 
Plasmin produced in the circulating system is rapidly neutralized by α2-antiplasmin. In 
addition, thrombolytic agents  have very short half-lives (Table 2.1) (42) which are the 
consequences of the fast renal clearance due to their hydrophilic properties and small 
size or the enzymatic degradation in blood, liver and kidney (27). Therefore, in order to 
be effective in clinic treatment, the infused dosage of thrombolytic agents must be 
sufficiently high enough over the period of time (e.g., I.V. infusion of SK for 12-72 h) 
to overcome their short half-lives (43). This leads to increase the side effects such as 
uncontrolled bleeding as well as the cost of treatment.  During thrombolysis, depletion 
of circulating plasminogen and plasma fibrinogen has been reported as a cause of 
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potential bleeding complications. The limited fibrin specificity and the nonspecific 
uptake of a large fraction of the administered drug dosage result in activation of 
circulating plasminogen to form plasmin, which, in turn, degrades plasma fibrinogen, 
leading to systemic hemorrhaging. There arises a need to use of advanced drug delivery 
systems to circumvent these problems and optimize efficacy and safety of thrombolytic 



















Table 2.1. Available Thrombolytic Agents (42) 
Name Mechanism of Action   Half-life 
tPA Fibrin-selective. Binds and activates fibrin by 
cleavage of an arginine-isoleucine bond after which it 




Irreversible binding and activation of SK to 
plasminogen. Indirect activation. Vaguely fibrin-
specific 
12-18 min 
Urokinase Cleavage of the Arg560-Val561 bond in plasminogen 
leading in active plasmin 
7-20 min 
Anisteplase Similar to SK 70-120 min 
Alteplase Tissue plasminogen activator produced by 
recombinant DNA technology. Fibrin-enhanced 
conversion of plasminogen to plasmin. It produces 
limited conversion of plasminogen in the absence of 
fibrin 
3-6 min 
Reteplase Similar to Alteplase. Lower fibrin binding and 
superior penetration ability 
14-18 min 




2.2.2. Streptokinase (SK) 
SK was first discovered by Tillet and Garner in 1933 (44). It is a 414-residue 
protein secreted by hemolytic strains of Streptococci with the molecular weight of 47 
kDa. The isoelectric pH for SK is 4.7 and it has a maximum activity at a pH of 
approximately 7.5. It consists of multiple structural domains (α-, β- and γ-domains) with 
different associated functional properties. The residues 1–59 of the α-domain play a key 
role in plasminogen activation (45). The C-terminal is involved in substrate recognition 
and activation. The Asp41-His48 region is an important region of SK for its binding to 
plasminogen. The β- and the γ-domain are involved in SK-plasminogen complex 
formation and the plasminogen activation process (3, 4).  
Unlike tPA and urokinase, SK possesses no enzymatic activity of its own and 
thus activates plasminogen (Pg) to produce plasmin (Pm) indirectly by forming a 
stoichiometric complex with either plasminogen or plasmin (2, 46). SK binds 
specifically to Pg and Pm, converting both the zymogen and proteinase into Pg 
activators. Binding of SK to Pg results in the conformational expression of an active 
catalytic site on the zymogen that cleaves specifically the Arg561-Val562 activation bond 
in the catalytic domain of Pg to form Pm (47, 48). SK also binds to Pm, transforming 
the substrate specificity of the proteinase from one which is incapable of Pg activation 
into a specific activator, and protects Pm from inactivation of α2-antiplasmin (47, 49).  
The mechanism of coupling between conformational activation and Pm 
formation by SK was investigated in kinetic studies (Figure 2.4) (50). The first step of 
the trigger catalytic cycle is rapid binding of SK to the catalytic domain of Pg and 
conformationally induced activation of Pg in the SK·Pg* catalytic complex. SK·Pg* 
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binds a second Pg molecule in the substrate mode and proteolytically activates it to Pm. 
Free Pm and free Pg compete for SK in the catalytic mode, where the formation of 
SK·Pm is highly preferred over SK·Pg* because of its 500–900-fold higher affinity. 
This results in transition of the catalytic complexes from SK·Pg* to SK·Pm as the sole 
catalyst, terminating the trigger cycle and initiating the bullet cycle. The SK·Pm 
catalytic complex binds free Pg as the substrate and proteolytically converts the 









The advantages of SK over other PAs include high catalytic efficiency in the 
reaction of plasminogen activation, low price, and extensive experience of clinical 
applications. Its disadvantages comprise low stability, immunogenicity, and rapid 
elimination from circulation (51). For improvement, efforts have focused primarily on 
structural modification of streptokinase in order to prolong its half-life, reduce or 
eliminate its immunogenicity, and enhance its resistance to the proteolytic action of 
plasmin (4). 
2.3. Development of drug carriers for prolonging the half-life of thrombolytic 
agents   
Drug delivery systems have the potential to help overcome the limitation and 
thereby broaden the therapeutic window of thrombolytic therapy through two keys: i) 
prolonging the circulation time and minimizing the side effects and ii) spatiotemporally 
localizing drug action (52). This dissertation focuses on the strategies to extend the half-
life of PAs. 
To increase the half-life and activity of PAs in the circulation, multiple 
approaches have been developed, including chemical modification (53, 54) and the use 
of drug carriers (5). PEGylation, the covalent attachment of polyethylene glycol (PEG) 
to proteins, has proven to enhance the therapeutic potentials of many proteins. PEG 
chains form a hydrated shell that masks the protein's surface and increases the 
molecular size of the polypeptide, thus reducing its renal ultrafiltration, preventing the 
approach of antibodies or antigen processing cells and reducing the degradation by 
proteolytic enzymes (55). PEGylation of tPA (53), SK (51, 56, 57), urokinase (58), and 
staphylokinase (59) has been prepared. The results showed that PEGylation has 
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significantly increased circulating time and stability in plasma, and reduced loss of 
activity and immunogenicity of the PAs.  
Another approach for prolonging the half-life of PAs is using properly designed 
drug carriers without chemical modification of these agents. Drug carriers can shield 
PAs for transport throughout the vasculature from premature inactivation, systemic 
removal or degradation by antibodies or enzymes. 
Liposomes, spherical vesicles with diameters from 100 to 250 nm, composed of 
a phospholipid bilayer surrounding an aqueous core, are widely investigated as drug 
carrier for thrombolytic agents in vitro and in vivo. They can entrap hydrophilic or 
hydrophobic drugs into their internal water compartment or into the membrane, making 
them to be isolated from the inactivating effect of external conditions and at the same 
time not causing any undesirable side effects (27, 60). By encapsulation in liposomes, 
the systemic delivery of PAs has been extended. 
As an approach to prolong the half-life of PAs, liposomes composed of 
distearoylphosphatidyl ethanolamine-N-poly(ethylene glycol) (DSPE-PEG2000) 
increased the half-life and improved the area under curve (AUC∞) of the SK by 16.3- 
and 6.1-fold, respectively, as compared to free SK (43). PEGylated liposomes 
composed of egg phosphatidylcholine, cholesterol and cholesterol-3-sulfate and DSPE-
PEG2000 prolong the half-life of tPA by 21-fold, compared to tPA alone (61). 
By encapsulation in large liposomes, Nguyen et al. showed that the fibrinolytic 
potential of SK was preserved because the liposomes limited its exposure to plasma 
components (16). Encapsulation of tPA, SK, urokinase in liposomes has demonstrated 
enhanced thrombolysis in vivo by reducing the time required to obtain reperfusion (16) 
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and increasing the percentage of the digested clot (62, 63) as compared with free PAs. 
In a jugular vein model in rabbit, liposomal tPA displayed a significantly better 
thrombolysis efficiency than equimolar doses of free tPA, in which a dose of about 0.24 
mg/kg of liposomal tPA was nearly as effective as 1.0 mg/kg free tPA (62). In a rabbit 
thrombosis model, SK-entrapped liposomes improved the thrombolysis by increasing a 
30% clot lysis as compared with free SK (63). 
The mechanism of acceleration of thrombolysis by encapsulated liposomes is 
not completely understood. The studies of Heeremans et al. and Perkin et al. in animal 
models demonstrated that increased thrombolytic effects of liposomes encapsulated PAs 
were not due to pressure at the leading edge of the thrombus created by blocking of the 
channels inside the thrombus (62, 63). Nguyen et al. suggested that the liposomes were 
ruptured due to the shear stress on the vesicles when they arrive at and begin to pass the 
clot. Then, the liposomes then release their payload and lysis begins (16). Other studies 
have shown that plasminogen binds to the surface of the liposome and acts as a homing 
device for the blood clot. Then, the plasminogen would reduce the free circulation of 
the liposomes and attract the encapsulated thrombolytic agent to the blood clot (9, 64). 
Although some benefits have been achieved from encapsulating PAs in 
liposomes, such delivery system suffers a limited stability. In order to develop 
encapsulated thrombolytic carriers with improved stability, polymeric carriers have 
been widely investigated to protect PAs from inactivation in the circulatory system and 
lengthen their short half-life (27). 
Leach et al. developed two types of drug carriers: liposome-encapsulated SK 
(LESK), and PEG-encapsulated SK microspheres (MESK). The in vivo results showed 
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that both the formulations improved thrombolysis for multiple end points when 
compared to free SK but MESK demonstrated comparatively better results. In a rabbit 
model of carotid artery thrombosis, MESK achieved accelerated thrombolysis with 
reduced residual clot mass and greater return of arterial blood flow when compared to 
both free SK and LESK (9). In a canine model of coronary artery thrombosis, MESK 
significantly reduced the time to achieve sustained reperfusion of the occluded artery, 
infarct size, residual clot mass, bleeding complication and reocclusion episodes (23). 
The mechanism  for increased thrombolysis by MESK was also explored: PEG polymer 
provides the resistance to adsorption and blocks the binding of SK to the leading edge 
of the thrombus, and enables the microspheres  to penetrate into the interior of the clot 
with the help of permeation pressure (65). This leading to the higher thrombolytic 
effects of MESK. 
In the absence of hydrodynamic pressure, the surface of the microparticles was 
modified to promote the interaction of the microparticles with the components of the 
clot in order to attract more particles into the interior of the clot. Following this trend, 
Chung et al. developed tPA loaded PLGA nanoparticles coated with chitosan (CS) and 
CS-GRGD (Gly-Arg-Gly-Asp peptides) to promote the electrostatic interactions 
between positive charge of CS and negative charge of fibrin as well as the ligand-
receptor interactions between GRGD and GP IIb/IIIa receptors expressed on the 
activated platelets. The results showed that PLGA/CS-GRGD nanoparticles achieved a 
nearly 40% shorter clot lysis time and more effective thrombolytic potential due to they 
were adhered more to the clot front and aggregated in the interior of the clot, compared 
to PLGA/CS and PLGA nanoparticles (17, 18).  
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With the development of nanotechnology in drug delivery, nanoparticles have 
been applied in thrombolytic therapy for effective delivery of thrombolytic agents to the 
site of thrombus and subsequently to the interior of the clot (37). Taking advantage of 
their small size, nanoparticles can avoid the resistance of the pores of fibrin clots to the 
penetration and permeation of drug carriers with size of 1 μm of larger (27). Piras et al. 
developed nanoparticles with an average diameter of 125–130 nm for targeting delivery 
as well as long circulation time (66). Nanoparticles was prepared as based on polymer 
which was synthesized by covalently binding of PEG moieties and monoclonal 
antibody anti-fibrin Fab fragment to the synthetic bioerodible copolymer chain, 
poly[(maleic anhydride)-alt-(butylvinyl ether)] (67). The results gave evidence that the 
release of enzyme from nanoparticles is time controlled and that nanoparticles have a 
preserving effect on urokinase activity in solution (66).  
Similarly, Tang et al. developed a tPA/gold nanoparticle (t-PA/AuNP) conjugate 
via bio-affinity ligation. The surfaces of gold nanoparticles were modified with 3-
lysine-terminated polyvinyl pyrrolidone, serving as a spacer. tPA was immobilized to 
the surface of gold nanoparticles under physiological conditions through affinity 
interactions between the specific domain in tPA and 3-lysine exposed on the 
nanoparticle surface. The results showed that the conjugate can not only retain almost 
full enzymatic activity and clot dissolving efficiency, but also protect tPA from 
inhibition by PAI-1 to some extent as compared with free tPA in vitro. Moreover, the 
conjugate showed prolonged circulation time in vivo (68).  
But concerns have been raised regarding the mechanisms of nanoparticles to 
concentrate locally at the thrombus site, and then, modulate the drug release nearby, 
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which restricted their use to treat acute events like acute myocardial infarction when 
immediate drug action is required (19). Recently, some approaches have used the 
targeting moieties such as anti-fibrin or anti-platelet antibodies for the delivery of 
nanocarriers to the thrombus site (37). Yurko et al. designed a prototype nanodevice 
capable of binding to fibrin clots and initiating their dissolution. The devices consist of 
tPA and anti-fibrin antibody covalently attached to a 40 nm polystyrene-latex 
nanoparticles. These nanoscale devices can directly deliver tPA to the clot site through 
fibrin-specific antibody. The results showed that in vitro fibrinolytic activity of these 
nanodevices was comparable to that of free tPA (69).  
Most recently, Korin et al described an alternative biomimetic approach based 
on high shear stress caused by vascular narrowing to trigger deliver of tPA rather than 
relying on molecular targeting or ultrasound (70). Shear-activated nanotherapeutics was 
prepared as aggregates of multiple smaller nanoparticles by spray-drying technique and 
was similar in size to nature platelets (1 to 5 μm in diameter). The nanoparticles were 
fabricated of PLGA and were further coated with tPA by means of biotin-streptavidin 
chemistry. Shear stress between 10 and 1000 dynes/cm
2
 caused aggregates of 
nanoparticles coated with tPA to burst apart, which then breaks down the clots. The 
results showed that when administered intravenously in mice, shear-activated 
nanotherapeutics clear rapidly clots induced by ferric chloride in mouse arteries, restore 
the normal flow, and increase survival in other fatal mouse pulmonary embolism model. 
This approach provides new potential treatment for vascular occluded diseases. 
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2.4. Development of Antibody Targeted Triggered Electrically Modified Prodrug 
Strategy (ATTEMPS)  
Despite the liposomes, microspheres and nanoparticles of PAs have been 
developed for extension of the half-life of PAs, the release of PAs from these 
formulations tends to be rather slow considering that a quick onset of action is required 
for treating acute thrombotic conditions. Therefore, a targeted prodrug approach where 
drug release can be triggered locally is necessary for treating thrombotic events. Yang 
and coworkers have pioneered the ATTEMPTS (antibody targeted, triggered, 
electrically modified prodrug strategy) concept for targeted and triggered delivery of 
thrombolytics (24-26, 71). This system is composed of two components: i) a targeting 
component consists of an anionic heparin molecule (Hep) conjugated to an anti-fibrin 
antibody (Ab) (termed Hep–Ab) and ii) a drug component consists of a cation-modified 
t-PA drug (termed CM-tPA) (Figure 2.5). These two components are linked via a tight 
yet reversible electrostatic interaction between the anionic heparin on the antibody and 
the cationic species on tPA. Once bound, the modified tPA is deprived of its enzymatic 
activity, due to blocking of the active site by the appended Hep–Ab conjugates. Thus, 
tPA will be inactive during administration. Once in circulation, the antibody component 
can direct the complex to reach the appropriate target site (fibrin clot), localizing and 
accumulating a high concentration of the inactivated CM-tPA at the thrombus. The 
active tPA can be subsequently released by the addition of protamine, a competitive 
heparin inhibitor, yielding dissolution of the clot. The results showed that both in vitro 
characterization and in vivo studies using a rat thrombosis model clearly demonstrated 
that Heb–Ab conjugate induced inhibition of CM-tPA could be effectively reversed 
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upon addition of protamine. Therefore, this delivery system would allow tPA to react 
only with plasminogen at the clot site, reducing bleeding complications associated with 
non-specific tPA action. Besides thrombolytics, this concept is also applicable to other 
macromolecular anticancer drug delivery offering a solution to overcoming dose-




Figure 2.5. Schematic Design of the ATTEMPTS Approach (26). 
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2.5. Reocclusion 
Thrombolytic therapy aims to restore the blood flow by dissolving or removing 
thrombotic material at the site of coronary lesion. However, the initially successful 
dissolution of the thrombus is complicated by reocclusion after thrombolysis. 
Reocclusion is a major drawback of thrombolytic therapy besides bleeding 
complications and resistance to thrombolysis. Reocclusion of coronary arteries after 
reperfusion occurs in 7-32% of patients (7). It has been associated with a 2- to 3-fold 
increased risk of mortality (8) and complications of left ventricular dysfunction, 
including heart failure and dysrhythmias (73).  
The mechanism of reocclusion is not well understood but it may be induced by  
plasmin-mediated activation of the coagulation system, procoagulant activity of the 
residual thrombus, presence of high shear forces that promote platelet deposition, and 
attenuation of physiologic fibrinolytic activity after thrombolysis (11). Early after 
reperfusion, the stimulus for reocclusion is strongest because of the re-exposure of the 
cracked plaque, the hypercoagulability and activation of platelets induced by 
thrombolytic therapy, and the presence of locally vasoactive substances released by 
activated platelets (74). The activation of platelets after thrombolysis and the released 
thrombin from the site of vascular injury due to the thrombus dissolution are mainly 
responsible for the pathogenesis of reocclusion. The residual thrombus may protrude 
into the lumen, leading to a small residual diameter and increasing local shear rate that 
promote platelet activation and deposition at the lesion are.  Moreover, the surface of 
residual thrombus is highly thrombogenic (10). Thrombin is bound to fibrin and 
remains active on the surface of the residual thrombus, where it may activate factors V 
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and VIII, promote fibrin formation and platelet activation. Thrombin activates platelets 
with subsequent elaboration of serotonin and thromboxane A2, which are not only 
vasoconstrictors but also strongly supports platelet aggregation which can contribute to 
early reocclusion (74, 75). Moreover, the residual fibrin-bound thrombin stimulates the 
formation of prothrombinase which, in turn, converts prothrombin to thrombin at a rate 
approximately 5 orders of magnitude greater than would normally occur in its absence 
(76).  
Multiple strategies have been applied to reduce the incidence of reocclusion 
after thrombolysis. Some strategies focus on inhibition of the platelet activation using 
antiplatelet agents (77, 78) or platelet glycoprotein IIb/IIIa inhibitors (79, 80). Another 
strategy is using anticoagulant agents as an adjunct to thrombolytic therapy in the 
treatment of patients with myocardial infarction (40). These studies have shown some 
benefits in preventing reocclusion. However, early reocclusion still occurs despite the 
use of such agents indicates the necessity for more potent interventions.  
In an attempt to prevent reocclusion, the structure of thrombolytic agents has 
been modified to have three parts: one part for activation of the fibrinolysis, another 
part to inhibit the aggregation of platelets and a third part to inhibit thrombin. Recently, 
a multifunctional recombinant staphylokinase linked with RGD (Arg-Gly-Asp) and 
Hirulog peptides was constructed in which RGD acts as an antiplatelet agent and 
Hirulog acts as an antithrombin agent (81). The results showed that the multifunctional 
staphylokinase retained the fibrinolytic activity and effectively inhibited the thrombin 
activity and platelet aggregation. The multifunctional staphylokinase can be an efficient 
candidate for reduction of reocclusion after thrombolysis 
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Alternative approach in prevention of reocclusion is to lyse the residual 
thrombus because of its procoagulant activity resulting in increased probability of 
reocclusion (11). Therefore, further lysis is required to reduce the rate of reocclusion 
following recanalization. Reocclusion after reperfusion has been noticed that it occurs 
in inverse proportion to the plasma half-life of the thrombolytic agent used (12). 
Accordingly, prolong the half-life of PAs by maintaining infusion of PAs after 
thrombolytic therapy was used to dissolve the residual thrombus for prevention of 
coronary artery reocclusion (13, 14). However, this approach suffered from the high 
risk of bleeding (15). It is therefore reasonable to assume that the infusion of PAs in a 
delivery vehicle would result in improved lysis by overcoming some their limitations, 
including short plasma half-life, rapid inactivation and clearance by PAI-1, circulating 
antibodies, and α2-antiplasmin. The new vehicle can be designed to maintain drug 
concentrations and prolong drug retention in the circulatory system in order to further 
lyse the residual thrombus.  
Recently, tPA-loaded liposomes have been developed and their surfaces have 
been decorated with a homing peptide that can guide the vehicle to accumulate on the 
thrombus and produce localized action (19). The liposomes demonstrated an affinity to 
bind with activated platelets and exhibited an initial burst release (40-50% in 30 min) 
followed by a continuous release of tPA (80-90% in 24 h) in vitro. The authors assume 
that 40-50% of tPA released during the burst phase would dissolve the existing clot, 
whereas continuous release thereafter would help prevent reocclusion. The results 
suggested that both reperfusion and prevention of reocclusion could be achieved by a 
single bolus dose with minimal systemic bleeding incidence. 
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In this study, we have developed formulations that would not only restore blood 
flow rapidly but would also act to prevent formation of another occlusion. We combine 
PEG microspheres which provide the release of the encapsulated SK on the scale of 
minutes for the clot digestion, with delayed release microspheres designed to prevent a 
putative second thrombus. The development of encapsulated thrombolytic formulations 


















Chapter 3 - Biphasic Release of Protein from Polyethylene Glycol 








Ischemia caused by the presence of an occlusive thrombus in a coronary or 
cerebral artery leads to the immediate result of a heart attack or stroke, possibly causing 
death. Administration of a “clot-busting” drug or plasminogen activator (PA) can break 
up the clot and restore flow with proven efficacy in saving lives and reducing morbidity 
if applied in a timely manner (82, 83). However, reocclusion of coronary arteries after 
thrombolytic therapy occurs in 7-32% of patients (7)
 
and increases the level of mortality 
(8). As mentioned in Chapter 2, the mechanism of reocclusion is obscure but it may be 
due to multiple factors including thrombi traveling downstream, the release of various 
chemicals that cause restenosis due to spasm of the blood vessel or the exposure of 
active surface that initiates platelet response (9). In clinical practice, reocclusion is 
addressed by administration of antithrombotic treatment following thrombolysis (78, 
84). But early reocclusion still occurs despite the use of such agents leading to the 
necessity for more potent and specific pharmaceutical procedures. 
                                                 
1
 This chapter has been published previously in Journal of Biomedical Materials Research Part 
A 2013, 101A: 2699-2705. This current version has been reformatted for this dissertation. 
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Encapsulation of antithrombotic agents in liposomes (85) and microcapsules has 
been used widely to modify their performance. Wang et al. (17) and Vaidya et al. (86) 
targeted nanoparticles and liposomes, respectively, with RGD (Arg-Gly-Asp) peptides 
on the surface of the delivery vehicles while others have investigated magnetic carriers 
to localize thrombolysis (87, 88). Similarly, ultrasound has been employed in 
combination with encapsulation with the objective of facilitating release at a specific 
site (89-91). Even in the absence of a targeting mechanism, significant acceleration of 
thrombolysis for faster reperfusion has been shown with encapsulation of streptokinase 
(SK) in polyethylene glycol (PEG) microspheres. PEG microspheres provide the release 
of the encapsulated PA on the scale of minutes, which dissolves blood clots more 
quickly by enabling PA administered intravenously to be delivered more effectively (9). 
While slow flow of free SK through a fresh thrombus coupled with the high surface 
area of fibrin strands results in thrombolysis only at the leading edge, encapsulation 
blocks the binding and enables penetration into the interior of the clot with faster 
digestion (65). Using an animal model of myocardial infarction, Leach also reported a 
reduction in reocclusion episodes with SK in rapid release microcapsules (23).
 
Coupling 
the extended circulatory lifetimes of tPA in PEGylated liposomes (61) with the fact that 
reocclusion varies inversely with plasma half-life (12) provides further indication of the 
potential of encapsulation to address a second occlusive event. Therefore, a time release 
frame of minutes is necessary to address an acute thrombotic crisis, while the release of 
a PA over several hours is desirable to address reocclusion. 
Polymers that have been widely used for controlled release of proteins and drugs 
over a period of days and months such as poly(D,L-lactic-co-glycolic acid) (PLGA) 
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(92) and poly(ε-caprolactone) (93) are not well-suited for addressing a secondary 
thrombus if one should form. Instead, a polymer that allows the release of active agent 
within hours is required. Dextran is a polysaccharide consisting mainly of linear 1,6-
glucosidic linkage with some degree of branching via 1,3-glucosidic linkage (94). It has 
great promise for drug delivery and has been used clinically as a plasma volume 
expander, peripheral flow promoter, and antithrombotic agent (95).
 
Due to a large 
number of hydroxyl groups, derivatives of the compound have been investigated as 
potential macromolecular carriers for the delivery of drugs and proteins (94-96) while a 
recent review highlights the potential of degradable dextran micro- and nano-particles 
for gene delivery (97).
 
Dextran, however, cannot be used directly for drug delivery itself 
due to its solubility in water. Therefore, mostly hydrophobically modified forms have 
been employed with solubility properties orthogonal to those of dextran (98-101). But 
depending on the extent of degree of substitution, i.e. the number of substituted groups 
in an anhydroglucose unit (AGU) (102), either water-soluble or water-insoluble dextran 
derivatives can be synthesized (99, 100). With the degree of substitution higher than 
1.75, dextran acetate (DA) is soluble in organic solvents and insoluble in distilled water 
(103). Water-insoluble DA is not suitable for delivery of PA because its degradation is 
on the scale of days (104).
 
As such, we have fabricated formulations that combine 
moderately water-soluble DA with PEG to create extended release microspheres by a 
modified double emulsion method. 
In this study, DAs were synthesized by the reaction of dextran with acetic 
anhydride, and then utilized to prepare PEG/DA microspheres by a modified double 
emulsion method. Bovine serum albumin (BSA) functioned as a model protein in order 
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to determine whether or not PEG/DA microspheres of various compositions were 
effective in providing release over a period of hours. Microsphere characteristics such 
as particle size, morphology, encapsulation efficiency, and time dependent in vitro drug 
release were investigated, and the release profile of PEG/DA microspheres compared 
with that of PEG microspheres. Lastly, as an illustration, we have predicted the mass of 
encapsulated BSA delivered at 3 hours for various mixtures of PEG and PEG/DA 
microspheres constrained to provide sufficient release at 30 minutes as would be needed 
for rapid perfusion. 
3.2. Materials and Methods  
3.2.1. Materials 
Dextran from Leuconostoc spp. (average molecular weight: 70 kDa), acetic 
anhydride, poly(vinyl alcohol) (PVA, 87-90% hydrolyzed, average  molecular weight: 
30-70 kDa), BSA, chloroform (HPLC grade), lithium chloride, dimethyl formamide 
(DMF, anhydrous 98%), triethylamine, and methylene chloride were purchased from 
Sigma-Aldrich (St. Louis, MO). PEG (molecular weight: 20 kDa) was obtained from 
Polysciences (Warrington, PA) and hexane (HPLC grade) from Fisher Scientific 
(Denver, CO).  
3.2.2. Synthesis of DA 
DA was synthesized by the reaction of dextran with acetic anhydride in a 
lithium chloride (LiCl/DMF 2% (w/v)) aprotic solvent system (105). 1 g dextran 
(hydroxyl group 0.0185 mol) was dissolved in 20 mL of LiCl/DMF at 90
o
C under 




triethylamine (20 mol% to acetic anhydride) was added to the reaction vessel. The 
solution was stirred for 15 min at 60
o
C, and then acetic anhydride was introduced at a 
very slow rate. In separate runs, the amount of acetic anhydride was 0.75, 1.0, and 1.5 
times the molarity of the hydroxyl group in the AGU of dextran and designated as DA1, 
DA2, and DA3, respectively. The reaction continued at 60
o
C for 10 h under nitrogen 
gas. Product isolation followed from precipitation in cold isopropyl alcohol, filtration 
and washing several times with isopropyl alcohol, before drying in a vacuum oven at 
room temperature. 
The degree of substitution was determined by a titration method (103, 106): 100 
mg of DA was dissolved in 10 mL of distilled water, and 20 mL of sodium hydroxide 
0.1N added. Phenolphthalein served as indicator. Excess base was titrated with 
hydrochloric acid 0.1N until a color change from pink to colorless occurred. A blank 
test was also carried out with dextran using the same procedure. 
The weight percent of the acetate group (A%) in the product and the degree of 
substitution were calculated using equations (1) and (2), respectively: 
 
A (%) = 




MWAGU × A 
(2) 
MWA × 100 – ΔAGU × A 
Equation (2) was derived from equation (3): 
A (%) = 
MWA × DS × 100 
(3) MWAGU + ΔAGU × DS 
       
  where 
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V1, V2: the volumes (mL) of HCl 0.1N used in titration for the blank and 
sample, respectively 
DS: degree of substitution 
NHCl: normality of hydrochloric acid 
MWA: molecular weight of the acetate group (43 g/mol)  
m: mass of DA (g) 
 MWAGU:  molecular weight of the AGU (162 g/mol) 
 ΔAGU: net increment in the AGU for every substituted acetate group (42 g/mol) 
3.2.3. Fourier Transform Infrared (FT-IR) Spectroscopy 
Infrared spectra were obtained by Nicolet 6700 FT-IR Spectrometer. Dried 
samples were ground with KBr powder, and pressed into pellets for FT-IR examination. 
3.2.4. Preparation of PEG/DAs Microspheres 
PEG/DAs microspheres were prepared by a modified double emulsion method 
(9). BSA (50 mg) and DA (0.3 g) were dissolved in 0.5 mL distilled water at room 
temperature. PEG (1 g) was dissolved separately in 1.5 mL chloroform. The two 
solutions were mixed and sonicated at 45 W for 1 min with a Sonic Dismembrator 60 
(Fisher Scientific). The protein/polymer mixture was mixed with 4 mL of PVA 2% 
(w/v). The mixture was vortexed for 40 s and frozen at -80
o
C for 1 h, and then 
lyophilized for 15 h. The lyophilized product was washed with hexane three times by 
centrifugation at 1000 × g for 5 min each at 4
o
C, and then was filtered under vacuum 
through 0.45 µm pore size membranes to remove any externally bound protein. Then, 
the washed particles were resuspended in hexane and were filtered under vacuum 
through 10 µm pore size membranes to remove the large particles. The particles were 
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isolated by centrifugation several times and finally dried in a fume hood for 1 h. Blank 
microspheres lacking entrapped BSA were prepared by replacing the BSA solution with 
an identical volume of distilled water.  
   Plain PEG microspheres were prepared by a modified double emulsion 
method without DA in inner water phase (65).  
3.2.5. Particle Size  
Particle diameter was determined using a laser diffraction particle size analyzer 
(Beckman Coulter LS230). The LS series uses light with a wavelength of 750 nm to 
measure sizes of particles ranging from 0.4 to 2000 µm. Microspheres (300 mg) were 
suspended in 3 mL of methylene chloride. Then, the microsphere suspension was 
loaded in the sample well, which had 700 mL of methylene chloride circulating 
throughout the system. Particle size measurements are based on diffraction patterns 
formed by the scattering of light by microparticles. Particle sizes were obtained and 
analyzed using the  accompanying software (107).
 
3.2.6. Morphology of the Microspheres 
The surface morphology of the microspheres was examined using a scanning 
electron microscope (SEM) (Jeol JSM-880). A small amount of freeze-dried 
microspheres was loaded on an aluminum stub with double-sided adhesive tape. 
Samples were sputter coated with gold and examined by SEM at 15 kV. 
To assess the mechanism of protein release from microspheres, the 
morphological change of PEG/DA3 microspheres in phosphate-buffered saline (PBS) 
pH 7.4 was monitored via SEM. Microspheres (100 mg) were dispersed in 10 mL PBS 
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pH 7.4 at 37
o
C. After 30 min, samples were collected by centrifuge at 1000 × g for 5 
min, and then lyophilized for 15-20 h. 
3.2.7. Drug Encapsulation Efficiency 
100 mg microspheres were allowed to dissolve completely in 10 mL distilled 
water for approximately 5 h. Protein concentration was determined by the bicinchoninic 
acid protein assay (Pierce Chemical, Rockford, IL). 
Encapsulation efficiency, EE (%), was calculated using the following equation: 
 
EE (%) = 
Actual BSA loading × 100 
(4) Total BSA  
 
3.2.8. In Vitro Release Study 
Microspheres (150 mg) were dispersed in 10 mL PBS pH 7.4 in test tubes.  The 
test tubes were placed in an orbital shaker at 37
o
C and agitated at 80 rpm. At specified 
time points, a small volume of solution (300 µL) was drawn for testing. Samples were 
collected using filters of 0.2 µm pore sizes and 25 mm diameter over 360 min. PBS 
solution (300 µL) was replenished to maintain a constant sink volume. The 
bicinchoninic acid method yielded the amount of the released protein. Similar tests were 
performed to analyze the dissolution of blank microspheres, and the corresponding 
absorbance of each blank sample as a function of time was subtracted from the 
absorbance of each sample. Samples were analyzed with Shimadzu UV-2450 
spectrophotometer at a wavelength of 562 nm (107). 
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3.2.9. Statistical Analysis 
Unless otherwise stated, all data are presented as mean ± standard error of the 
mean. The Student’s t-test was used to determine significance between two groups. P-
values less than 0.05 were considered significant.  
3.3. Results and Discussion 
3.3.1. Synthesis and Characterization of DA  
In the present study, dextran was modified by acetylating a fraction of the 
hydroxyl groups of dextran to produce a hydrophobically modified dextran, DA (Figure 
3.1). Esterification of hydroxyl groups in dextran proceeded by reaction with varying 
amounts of acetic anhydride. The degree of substitution of DA in different preparations 
appears in Table 3.1. The weight percent of the acetyl group (A%) and the degree of 
substitution increased with increasing molar ratio of acetic anhydride to hydroxyl 
groups of dextran. Dextran is (1 → 6) linked α-D-glucopyranosyl residues and carries 
three hydroxyl groups per AGU (105). As shown in Table 3.1, the degrees of 
substitution of DAs were 0.60 – 0.96, indicating that only 0.60 – 0.96 of available 
hydroxyl groups of AGU were modified. Increasing degree of substitution of DA means 
increasing the introduction of acetyl groups into the backbone of dextran, resulting in 
increasing the hydrophobicity of dextran. Because of low degree of substitution, DA1, 
DA2 and DA3 were soluble in distilled water and insoluble in organic solvents such as 
chloroform and methylene chloride. The solubility of DAs in water is DA1>DA2>DA3. 
DAs with higher degree of substitution, which also were prepared, exhibited orthogonal 
properties, insoluble in water, and not suited for encapsulation in this study.  
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Table 3.1. Results of Acetylation of Dextran with Acetic Anhydride (AA) (n = 5) 
Sample Molar Ratio
a
 Yield (%) Acetyl Group 
(A%) 
Degree of     
Substitution 
DA1 1:0.75 82 13.8 0.60 
DA2 1:1 80 17.2 0.78 






Figure 3.1. Synthesis of DA. 
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The FT-IR spectra of DA (Figure 3.2) confirmed introduction of the acetyl 
group, as indicated by C=O stretching of ester at 1735 cm
-1
, and the C-O-C stretching of 
esters at 1250 cm
-1
. The original dextran did not show such a carbonyl peak. A broad 
peak about 3500 cm
-1 
was related to the OH absorption of the unreacted hydroxyl 








3.3.2. Preparation and Characterization of PEG/DAs Microspheres 
PEG was used as the major encapsulation vehicle due to its excellent solubility 
in aqueous and organic solvents, biocompatibility, and ability to inhibit adhesion to 
protein. The DAs obtained were insoluble in organic solvents but with the help of PEG, 
PEG/DA could serve as drug carrier. With the double emulsion method, protein and DA 
were dissolved in distilled water, while PEG was dissolved in chloroform. When the 
two solutions were mixed with the help of an emulsifier (PVA 2% w/v), the hydrophilic 
and hydrophobic components partitioned themselves so that the polymers entrapped 
protein.  
The results of SEM demonstrated that the shape of PEG/DAs microspheres was 
spherical (Figure 3.3) with a particle size less than 1 µm. The particle size by SEM was 
confirmed with that found by a light scattering analyzer. As shown in Table 3.2, the 
particle sizes of PEG/DAs microspheres were 0.74 – 0.85 µm in diameter, increasing as 
the degree of substitution of DA increased. An increase in the degree of substitution 
results in an increase in the molecular weight of the dextran derivatives (108). 
Increasing the molecular weight of DAs enhanced the viscosity of the aqueous phase, 
which reduces the efficiency of mixing and formation of larger emulsion droplets. Thus, 
the higher DA resulted in larger particles. In Figure 3.3A, the background of the image 





Table 3.2. Characterization of PEG Microspheres and PEG/DAs Microspheres
a
 (mean ± 








EE (%) t90% (min)
b 
PEG _ 0.759 ± 0.018 53.2 ± 1.5 21 
PEG/DA1 0.60 0.743 ± 0.009 56.3 ± 1.2 31 
PEG/DA2 0.78 0.817 ± 0.005* 61.7 ± 2.0* 69 
PEG/DA3 0.96 0.851 ± 0.011*†§ 70.5 ± 3.4*†§ 118 
a 
PEG/DA microspheres prepared with 1 g PEG and 0.3 g modified dextran 
b 
time to release 90% of the encapsulated BSA 






Figure 3.3. SEM Images of PEG/DAs Microspheres: (A) PEG/DA1, (B) PEG/DA2, 
and (C) PEG/DA3 Microspheres 
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The EE (%) of PEG/DAs microspheres was found to depend on the degree of 
substitution (Table 3.2). The encapsulation efficiency increased from 56.3 ± 1.2% to 
70.5 ± 3.4% with the degree of substitution of DA increasing from 0.60 to 0.96. Higher 
degree of substitution was associated with improvements in the encapsulation efficiency 
due to enhanced interactions. These interactions include hydrogen bonding between 
amine and carboxylic groups in BSA, and hydroxyl groups in DA as well as 
hydrophobic interactions between hydrophobic amino acids of BSA (109) and the 
acetyl group in DA during emulsification (104). The encapsulation efficiency of PEG 
microspheres was lower than that of PEG/DAs microspheres due to the lack of 
hydrophobic bonding. 
3.3.3. In Vitro Release Study 
To study the protein release behavior, PEG/DAs microspheres were suspended 
in PBS pH 7.4 and the free protein level in vitro determined as a function of time. The 
release of BSA from PEG/DAs microspheres was comprised of a reduced initial “burst 
phase” followed by a slower “sustained release phase” (Figure 3.4). PEG/DA1 
microspheres exhibited the fastest release of BSA while PEG/DA3 microspheres 





Figure 3.4. In Vitro Release Study of BSA from PEG and PEG/DAs Microspheres 
(mean ± standard error of the mean, n = 5). 
 
 
t90%, defined as the time to release 90% of the encapsulated BSA, was found 
from release profiles for different PEG/DAs microspheres. The longer t90%, the larger 
reduction of the burst effect. As shown in Table 3.2, t90% increased from 31 to 118 min 
as the degree of substitution of DA rose from 0.60 to 0.96. In contrast, t90% of plain PEG 
microspheres was 21 min. Not surprisingly, the release of BSA from PEG microspheres 
was very fast due to the high solubility of PEG in water. These results indicated that 
greater hydrophobicity of DA leads to slower release of BSA from microspheres as 
expected. The release rate of BSA depended on the degree of substitution because the 
enhanced interactions between BSA and DAs contribute to prevent fragmentation of the 
microspheres, resulting in a reduction of the initial burst. Moreover, higher degrees of 
substitution led to fewer favorable interactions with solvent as well as larger particles 
which dissolve more slowly than smaller particles. With a t90% of 118 min, PEG/DA3 
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microspheres provided the release of BSA on the scale of hours (180 min). This is a 
promising observation for the prevention of reocclusion of an artery because 
complementary action to rapid reperfusion with delayed release of a PA appears viable. 
The morphological change of PEG/DA3 microspheres in PBS pH 7.4 solution 
was investigated via SEM. After 30 min, swelling and loss of spherical shape of 
microspheres were observed (Figure 3.5). Properties of the constituent polymers help to 
explain the mechanism of release and the distorted shape. On contact with water, PEG 
and dextran absorb water and swell due to their hydrophylicity (110-112), leading to 
release of protein and an increase in size of the microspheres by an order of magnitude. 
Distortion can be attributed to microphase separation of the polymers and stresses 
resulting from a difference in swelling ratio of PEG and DA. Swelling ratio is generally 
important when discussing crosslinked hydrogels which have been made of PEG and 
dextran. But this does not apply for this system since there are no crosslinks. In the 
absence of crosslinks to maintain a monolithic structure, no final expansion point exists 
to determine a specific swelling ratio. With size of 5-10 μm, it can be expected that 
microparticles may be removed by the reticuloendothelial system (RES) and some may 
block capillaries until they dissolve. 
 





3.3.4. Calculation of the Amount of BSA Released In Vitro from Mixtures of PEG 
and PEG/DA3 Microspheres 
If a mixture of PEG and PEG/DA3 microspheres is used to encapsulate a PA for 
thrombolysis, we hypothesize that the amount of encapsulated PA released from the 
mixture at 30 min is sufficient for rapid perfusion while the amount released afterward 
up to 180 min might address reocclusion. The concept of using a mixture of 
microspheres allows for design to achieve the dual functionality. This can be 
demonstrated computationally for the release of BSA. 
For this purpose, BSA was used as a model protein for predicting the amount of 
an active agent released in vitro from the mixtures of PEG and PEG/DA microspheres.  
Mathematical fits were obtained for release rates from PEG and PEG/DA3 
microspheres (Figure 3.6) to predict amount delivered in vitro over a period of hours 
when constrained to a target level at 30 min. Results for BSA mass released in vitro at 
different times for various mixtures of PEG and PEG/DA3 microspheres are presented 




Figure 3.6. Release Data for PEG and PEG/DA3 Microspheres with Linearized 
Regression Fit [YPEG = 100(1 – e
−0.12t





Table 3.3. Prediction of BSA Released In Vitro from Mixtures of PEG and PEG/DA3 
Microspheres Subject to a Target Level for 30 min 
 
Mixture BSA Encapsulated 
in PEG 
Microspheres (mg) 
BSA Encapsulated in 
PEG/DA3 
Microspheres (mg) 
Released BSA Mass 
(mg) 
30 min 180 min 
1 10 40 30.26 49.47 
2 15 30 29.99 44.60 
3 20 20 29.72 39.73 
4 25 10 29.45 34.87 





In clinical practice, it should be appreciated that the dynamics of the fibrinolytic 
system are very complex with many species involved (113).
 
The initial delivery of a PA 
rapidly depletes the circulatory concentration of plasminogen. Sustained release allows 
time for recovery of plasminogen concentration, but also inhibitors, e.g. PAI-1, 
circulating antibodies and α2-antiplasmin. Events at the residual thrombus where lysis 
and clot formation compete are most important. On the basis of half-life data, this 
approach can be expected to favor the former. 
3.4. Conclusions 
In this study, DAs with various degrees of substitution were successfully 
synthesized by the reaction of dextran with acetic anhydride in LiCl/DMF 2% (w/v) 
system in an effort to prepare the slow-acting microspheres via the modified double 
emulsion method. Particle size, EE (%), and release rate of PEG/DAs microspheres 
depended on the degree of substitution of DA. Increasing the degree of substitution of 
DA resulted in increases of particle size and EE (%), and a slower release rate of protein 
from PEG/DAs microspheres. PEG/DA3 microspheres exhibited the release of BSA on 
the scale of hours (180 min), more slowly than that of PEG microspheres. The amount 
of BSA released from mixtures of PEG and PEG/DA3 microspheres was calculated 
mathematically to predict delivery in vitro over a period of hours when constrained at 
30 min. Therefore, the mixtures of PEG and PEG/DA3 microspheres can be considered 
as a promising means to prevent reocclusion after thrombolysis, in addition to 
addressing the initial thrombotic crisis.  
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Chapter 4 - A Mixture of Polyethylene Glycol and Chitosan-Eudragit 
Microspheres for a Rapid Reperfusion and Prevention of Reocclusion 







Cardiovascular disease is considered to be the primary cause of death in the 
United States. More than 83 million Americans have been diagnosed with one or more 
types of cardiovascular disease (1), including coronary heart disease, stroke, deep vein 
thrombosis, and pulmonary embolism (27). Formation of an occlusive blood clot inside 
a blood vessel is a leading cause of common cardiovascular disease. Thrombolytic 
therapy is an available means to dissolve the occlusive thrombus and achieve patency 
besides other methods such as angioplasty and stent placement. This method includes 
administration of a plasminogen activator (PA) [e.g. tissue-type plasminogen activator 
(tPA), streptokinase (SK), urokinase] to break up the clot and restore flow (4). The 
major goal of thrombolytic therapy for myocardial infarction is to minimize the time 
during which the coronary artery remains occluded by rapidly achieving reperfusion 
and salvaging tissue. However, after achievement of reperfusion, a putative second 
thrombus may occur at the site leading to formation of another blockage (114). 
                                                 
2
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Reocclusion of coronary arteries after thrombolytic therapy occurs in 7–32% of patients 
(7) and increases the level of mortality (8). 
Encapsulation shows great promise in improving the performance of PAs. PA-
containing liposomes and nano- or microspheres accelerate thrombolysis by providing a 
rapid release of PAs near or even within blood clot regions (17, 65, 86), so that blood 
clots dissolve more quickly (9, 18, 115, 116). Drug carriers with PAs have been targeted 
to thrombi by attaching ligands, e.g. RGD (Arg-Gly-Asp) peptides or gamma-chain 
peptide sequence of fibrinogen, to the surface of liposomes and nanoparticles (17, 19, 
86) or by using magnetic nanoparticles to localize thrombolysis (20, 21). Similarly, 
ultrasound has been used in combination with encapsulation to facilitate release at the 
clot site (90, 91, 117). In a novel approach, Korin et al. (70) have proposed shear 
activation of PA-containing nanoparticles as a targeting strategy which might show 
promise in addressing the channeling phenomenon that can occur with thrombolysis. 
Results with drug delivery systems like these indicate their great potential for 
fibrinolytic therapy including a recent report that liposomal encapsulated tPA attenuates 
bleeding complications (19) 
However, the above strategies only focus on improvement in the delivery of the 
PAs to the site of thrombus for a rapid reperfusion and a decrease of bleeding 
complications, not on prevention of reocclusion after thrombolysis. Encapsulation 
enhances the efficacy of PAs in part by protection of these agents from the premature 
inactivation by antibodies or PAI-1 in the circulation, yielding increased half-lives and 
thus showing some promise in addressing reocclusion (9, 16, 66, 118). A link between 
half-life and reocclusion has long been known (12, 61) and experiment confirms the 
50 
expectation with encapsulation. Specifically, Leach et al. (23) observed fewer 
reocclusion episodes with SK in polyethylene glycol (PEG) microspheres in an animal 
model of myocardial infarction.  
The purpose of this study is to examine formulations that would not only restore 
blood flow rapidly, but also would act to prevent formation of another blockage and 
further loss of tissue. We have developed microspheres which exhibit the release of 
active agent on the scale of hours. These microspheres can be used with PEG 
microspheres, which dissolve in minutes, to provide complementary action with delayed 
release to prevent a putative second thrombus. We used polymethacrylate polymer 
(Eudragit FS30D) for development and testing of delayed release microspheres. 
Eudragit FS30D (termed Eud hereafter) is the trade name of a copolymer of methyl 
acrylate, methyl methacrylate and methacrylic acid which is soluble at pH above 7.0, 
and is commonly used in pharmaceutical industry for drug controlled-release (119). In 
addition, Eud microspheres were modified with chitosan (CS), as CS has been shown to 
be a biodegradable, biocompatible and non-toxic natural polymer (120), widely applied 
in drug delivery systems (121, 122) and for tissue engineering constructs (123). 
Experiments included the preparation and characterization of Eud/SK and CS-Eud/SK 
microspheres, and an in vitro thrombolytic study for testing the protracted clot-lytic 
efficacy of mixtures of PEG/SK and Eud/SK microspheres and mixtures of PEG/SK 
and CS-Eud/SK microspheres.  
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4.2. Materials and Methods 
4.2.1. Materials 
CS (medium molecular weight: 190-310 kDa) with 75-85% deacetylation, 
poly(vinyl alcohol) (PVA, 87-90% hydrolyzed, average  molecular weight: 30-70 kDa), 
BSA, methylene chloride, 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC), N-
hydroxysuccinimide (NHS), 2-(N-morpholino)ethanesulfonic acid (MES), SK (10,000 
IU) were purchased from Sigma-Aldrich (St. Louis, MO). PEG (molecular weight: 20 
kDa) was obtained from Polysciences (Warrington, PA). Eud FS30D [poly(methyl 
acrylate-co-methyl methacrylate-co-methacrylic acid) = 7:3:1] (average  molecular 
weight: 220 kDa) was a gift from Evonik Röhm GmbH (Darmstadt, Germany). Eud was 
supplied in a form of an aqueous dispersion with 30 % dry substance. The product was 
purified by dialysis of the solution against distilled water for 2 days using a regenerated 
cellulose membrane with a MWCO of 3500 g/mol (Fisherbrand, Fisher Scientific). 
Then, the sample was lyophilized for 24 h to obtain a white powder. 
4.2.2. Preparation of Eud/SK Microspheres 
Eud/SK microspheres were prepared by a double emulsion method (124). 
Briefly, SK (250,000 IU) was dissolved in 0.5 mL distilled water at room temperature. 
Eud (0.5 g) was dissolved separately in 5 mL methylene chloride and added to SK 
solution. This mixture was sonicated at 60 W for 45 s using a Sonic Dismembrator 60 
(Fisher Scientific). The primary emulsion was mixed with 10 mL of PVA 3% (w/v), 
vortexed for 30 s, and sonicated at 60 W for 30 s to produce W/O/W emulsion. Then, 
100 mL of PVA 0.3% (w/v) was added to the emulsion. The suspension was 
mechanically stirred at 1200 rpm for 6 h at room temperature to remove the organic 
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solvent. The microspheres were isolated by centrifugation (1000 × g for 10 min) and 
washed with distilled water by vortexing for 30 s and then centrifuging several times to 
remove the residual PVA and solvent. The washed microspheres were suspended in 
distilled water (2 mL) and lyophilized for 20 h. 
4.2.3. Preparation of CS-Eud/SK Microspheres 
0.3 g Eud/SK microspheres was dispersed in 10 mL MES (pH 5.5) containing 
EDC (0.3 g) and NHS (0.2 g) (the molar ration of EDC to NHS = 1:1.1) for 60 min. 
Then, 20 mL of 1.5% (w/v) CS solution in 1% acetic acid was added to this suspension 
(mass ratio of Eud to CS =1:1) and the mixture stirred for 24 h at room temperature.  
Microspheres were collected by centrifugation (1000 × g for 10 min) and washed 
several times with distilled water by vortexing for 30 s and then centrifuging. Washed 
microspheres were suspended in distilled water (2 mL) and lyophilized for 20 h (125). 
4.2.4. Particle Size  
Particle diameter was determined using a laser diffraction particle size analyzer 
(Beckman Coulter LS230). Particle size measurements are based on diffraction patterns 
formed by the scattering of light by microparticles. Particle sizes were obtained and 
analyzed using the accompanying software of the instrument. 
4.2.5. Drug Encapsulation Efficiency 
Encapsulation efficiency (EE) of Eud/SK and CS-Eud/SK microspheres was 
determined with commercial assay both by the protein content present in the 
microspheres as well as the activity of the protein. Activity of SK is normally expressed 
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by international unit (IU) in which one IU was defined as the amount of enzyme activity 
that converts 1 μmol of substrate per minute per liter (126). 
The content of entrapped SK in the microspheres was determined using the 
bicinchoninic acid protein assay (Pierce Chemical, Rockford, IL) after dissolving the 
microspheres (10 mg in 2 mL PBS pH 7.4) completely for 24 h. The concentration of 
the dissolved SK was determined spectrophotometrically at 562 nm (Shimadzu UV-
2450). Samples were compared to that of a standard curve of SK with blank 
microspheres (9, 65).  
The activity of encapsulated SK was determined using a chromogenic assay 
(Sekisui Diagnostics, Stamford, CT) (65, 126) after dissolving the microspheres (5 mg 
in 1 mL PBS pH 7.4) completely for 24 h. Samples were collected, incubated with fresh 
plasma at 37
o
C in a 96-well plate for 1 min, allowing the formation of the plasminogen-
SK complex. The plasmin-lysis chromogenic substrate (S-2251) was added to the 
complex. The substrate was cleaved by the plasmin, releasing p-nitroaniline which was 
measured spectrophotometrically at 405 nm (Synergy HT plate reader, Bio-Tek). The 
photometric signal was linear with respect to activity of SK originally present in the 
samples compared to that of a standard curve of SK with blank microspheres. 
EE (%) was calculated using the following equation: 
 
𝐸𝐸(%) =
𝐴𝑐𝑡𝑢𝑎𝑙 𝑆𝐾 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 (𝑐𝑜𝑛𝑡𝑒𝑛𝑡 𝑜𝑟 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦) × 100




4.2.6. Morphology of the Microspheres 
The surface morphology of the microspheres was examined using a scanning 
electron microscope (SEM) (JEOLJSM-880). A small amount of freeze-dried 
microspheres was loaded on an aluminum stub with double-sided adhesive tape. 
Samples were sputter coated with gold and examined by SEM at 15 kV. 
Particle morphology was also studied using a transmission electron microscope 
(TEM) (JEOL 2000-FX). A small amount of microspheres was placed on a 300 mesh 
copper grid coated with carbon film and stained by 2% (w/v) phosphotungstic acid. 
Then, after the samples were air-dried at room temperature, the morphology of the 
stained microspheres was imaged by TEM. 
To assess the mechanism of SK release from CS-Eud/SK microspheres, the 
morphological change of CS-Eud/SK microspheres in PBS pH 7.4 was monitored via 
SEM. Microspheres (20 mg) were dispersed in 10 mL PBS pH 7.4 at 37
o
C. After 2 h 
and 6 h, samples were collected by centrifuge at 1000 × g for 10 min and then 
lyophilized for 15–20 h. 
4.2.7. Fourier Transform Infrared (FT-IR) Spectroscopy 
Infrared spectra were obtained by Nicolet 6700 FT-IR Spectrometer. Dried 
samples (CS, blank Eud and CS-Eud microspheres) were ground with KBr powder, and 
pressed into pellets for FT-IR examination. 
4.2.8. Preparation of PEG/SK Microspheres 
PEG/SK microspheres were prepared by a modified double emulsion method in 
which 100,000 IU of SK was encapsulated in 1 g of PEG, as described earlier (9, 65). 
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The content and activity of encapsulated SK were determined using the above described 
bicinchoninic acid protein assay and chromogenic assay. 
4.2.9. In Vitro Release Study:  
Eud/SK or CS-Eud/SK microspheres (50 mg) were dispersed in 25 mL PBS pH 
7.4 in test tubes, respectively. The test tubes were placed in an orbital shaker at 37
o
C 
and agitated at 80 rpm. At specified time points, a small volume of solution (1 mL) was 
drawn for testing. Samples were collected using filters of 0.2 µm pore sizes and 25 mm 
diameter over 12 h. PBS pH 7.4 solution was replenished to maintain a constant sink 
volume. The amount of SK release was determined using the above described 
bicinchoninic acid method. 
To determine the SK release from mixtures of microspheres, a mixture of 
PEG/SK microspheres (50 mg) and Eud/SK microspheres (90 mg) or of PEG/SK 
microspheres (50 mg) and CS-Eud/SK microspheres (100 mg) were dispersed in 25 mL 
PBS pH 7.4 in test tubes, separately. The test tubes were placed in an orbital shaker at 
37
o
C and agitated at 80 rpm. At specified time points, a small volume of solution (1 
mL) was drawn for testing. PBS solution was replenished to maintain a constant sink 
volume. The amount of SK release was determined using the above described   
chromogenic assay. 
The in vitro release profiles of SK were fitted to the zero-order model, first-
order model, Higuchi square root model and Hixson–Crowell cube root model (127, 
128). The model with the highest correlation coefficient between the experimentally 
obtained data and the fitted data was selected. 
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 4.2.10. In Vitro Thrombolytic Study  
4.2.10.1. Preparation of Plasma Blood Clot 
A blood clot was formed in  a  0.2 cm (ID) glass capillary tube (Fisher 
Scientific) as described previously (65, 129). Briefly, the capillary tubes were etched in 
a dilute solution of hydrofluoric acid and the interior surface coated with a thin layer of 
fibrin for enhancement of clot adherence. Blood samples were collected from healthy 
donors and anticoagulated with 0.13 M sodium citrate (1: 9 in volume). Platelet-rich 
plasma (PRP) and platelet-poor plasma (PPP) were obtained by centrifugation of blood 
collection tube in a centrifuge (Beckman AccuSpin) at 150 × g for 10 min and 4600 × g 
for 20 min, respectively. Then, a small volume of the mixture of 50 µL PRP, 50 µL 
PPP, 100 µL thrombin 2 NIH/mL and 16 µL of 0.25 M CaCl2 was injected into a 
capillary tube and then left to form a 3-cm plasma clot for 1 h at 37
o
C. 
4.2.10.2. In Vitro Lysis Study 
Study formulations included: free SK, PEG/SK, Eud/SK and CS-Eud/SK 
microspheres. Encapsulated SK in PEG/SK microspheres was 2500 IU (approximately 
50 mg of microspheres), in Eud/SK microspheres was 12500 IU (approximately 90 mg 
of microspheres), and in CS-Eud/SK microspheres was 12500 IU (approximately 100 
mg of microspheres).  Four fibrinolytic formulation mixtures were studied (Table 4.1):   
I) Free SK (2500 IU) + Blank CS-Eud microspheres  
II) PEG/SK (2500 IU) microspheres + Free SK (12500 IU)/Blank CS-Eud 
microspheres  
III) PEG/SK (2500 IU) microspheres + Eud/SK (12500 IU) microspheres,  
IV) PEG/SK (2500 IU) microspheres + CS-Eud/SK (12500 IU) microspheres.  
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Table 4.1. Fibrinolytic Formulation Mixtures 
Formulation 
Streptokinase (IU) 
Free SK PEG/SK Eud/SK CS-Eud/SK 
I 2500 – – 0 
II 12500 2500 – 0 
III – 2500 12500 – 
IV – 2500 – 12500 
 
 
The dose fractionation of SK activity between PEG/SK and Eud/SK 
microspheres or CS-Eud/SK microspheres was 1: 5. The lysis study consisted of a series 
of experiments with a lysis test immediately after addition of the microspheres to 
plasma and additional lysis tests after the microspheres were exposed to plasma for 
periods of 2 h, 4 h and 6 h. 
To carry out a lysis test, an occluded capillary tube oriented vertically was 
connected by Tygon lab tubing to a horizontally mounted graduated glass pipette. The 
height of the tubing from the upper surface of the plasma clot to the glass pipette was 61 
cm. Firstly, the glass pipette and tubing were filled with a solution of 5 mL PBS pH 7.4, 
2 mL PPP (as a source of plasminogen), and the fibrinolytic formulation mixtures. 
Then, the glass pipette was connected to a PBS buffer reservoir to achieve a hydrostatic 
pressure of 45 mm Hg/3-cm clot. Pressure was kept constant throughout the experiment. 
The lysis time required to dissolve the clot was monitored. The mixture in the collection 
dish was retained for the next stage of the lysis experiment (Figure 4.1). 
For a series of “reocclusion” lysis experiments at 2 h, 4 h and 6 h, the mixture in 
the collection dish was centrifugated at 1000 × g for 10 min, rinsed with distilled water 
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and centrifuged again to collect the undissolved microspheres. The glass pipette was 
filled with the mixture of the obtained microspheres in 5 mL PBS at pH 7.4, and 2 mL 
PPP and connected to another occluded capillary tube representing a secondary 
thrombus. The clot lysis time was recorded and the mixture in the collection dish was 




































Figure 4.2. Reocclusion Lysis Test Scheme. 
 
 
4.2.11. Statistical Analysis: 
Unless otherwise stated, all data are presented as mean ± standard error of the 
mean. Student’s t-test was used to determine significance between two groups. P-values 
less than 0.05 were considered significant. 
4.3. Results 
4.3.1. Characterization of Eud/SK and CS-Eud/SK Microspheres  
Eud/SK microspheres were successfully prepared using the double emulsion 
method. CS-Eud/SK microspheres were formed by surface modification of Eud/SK 
microspheres with CS using covalent bond synthesis (Figure 4.3). In this method, the 
carboxyl group of Eud was chemically coupled with the primary amino group of CS by 
EDC/NHS. Firstly, carboxyl groups on the surface of Eud/SK microspheres were 
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Figure 4.3. Preparation of Eud/SK and CS-Eud/SK Microspheres: 
(i) Preparation of Eud/SK Microspheres via the Double Emulsion Method. 
(ii) Activation of Carboxyl Group on the Surface of Microspheres by EDC/NHS. 
(iii) Reaction of Activated Carboxyl Group with Amine Group of CS. 
 
 
FT-IR spectra confirmed the successful conjugation of CS to the Eud 
microspheres (Figure 4.4). In the spectra of blank Eud and CS-Eud microspheres, the 
peaks at 1735 and 1733 cm
-1
, respectively, correspond to the C=O stretching vibration 
from carboxylic acid groups (131). The spectrum of CS exhibits peaks of amide groups: 
amide I band (C=O stretch of acetyl group) at 1654 cm
-1
 and amide II band (N-H 
stretch) at 1570 cm
-1
 (125) while the spectrum of blank CS-Eud microspheres displays 






Figure 4.4. FT-IR Spectra of CS, Blank Eud and CS-Eud Microspheres: (A) CS, (B) 
Blank Eud Microspheres, and (C) Blank CS-Eud microspheres. 
 
 
The EE (%) based on protein content or protein activity of CS-Eud/SK 
microspheres was significant lower than that of Eud/SK microspheres (Table 4.2). The 
EE (%) of CS-Eud/SK microspheres was determined based on the content or activity of 
SK obtained after the covalent bonding process over the initial total content or activity 
of SK, while the EE (%) of Eud/SK microspheres was determined based on the content 
or activity of SK obtained before the covalent bonding process over the same initial 
total content or activity of SK according to equation (5). The EE (%) based on protein 
content or protein activity of PEG/SK microspheres has also been presented in Table 











Table 4.2. Characterization of PEG/SK, Eud/SK and CS-Eud/SK Microspheres (mean 








Protein Content Activity 
PEG/SK 0.802 ± 0.023 84.4 ± 3.1 52.6 ± 2.8 
Eud/SK 0.726 ± 0.015 90.1 ± 2.7 61.4 ± 3.4 
CS-Eud/SK 0.813 ± 0.018* 85.3 ± 2.2* 50.6 ± 2.9* 
* = p<0.05 vs. Eud/SK 
 
 
SEM images confirmed that the shapes of Eud/SK and CS-Eud/SK microspheres 
were spherical with smooth surface and a particle size less than 1 µm (Figure 4.5). 
Moreover, the particle size by SEM confirmed that found by light scattering where 
Eud/SK microspheres had a particle size of 0.726 ± 0.015 µm. A statistically significant 
difference in size was observed after modification with CS. The mean particle diameter 
of Eud/SK microspheres was smaller than that of CS-Eud/SK microspheres (0.726 ± 
0.015 µm vs 0.813 ± 0.018 µm, p<0.05) (Table 4.2). The increase in size of CS-Eud/SK 
microspheres in comparison with that of Eud/SK microspheres was attributed to 








TEM images showed that Eud/SK and CS-Eud/SK microspheres were non-
homogenous matrices due to the different ratios of components in Eud copolymer 
(methylacrylate:methylmethacrylate:methacrylic acid = 7:3:1). Furthermore, under the 
TEM microscope, CS-Eud/SK microspheres were darker than Eud/SK microspheres 
(Figure 4.6). The component of the dark clustered layers on the surface of CS-Eud/SK 
microspheres was CS (132). CS layers did not coat the entire surface of the Eud/SK 
microspheres because the carboxyl groups were randomly distributed along the 
copolymer chain and the ratio of the free carboxyl groups to the ester groups is 
approximately 1:10. When conjugating to the carboxyl groups on the surface of Eud/SK 
microspheres, CS formed nonuniformly clustered layers over the surface, perhaps due 
















The in vitro release profiles of the Eud/SK and CS-Eud/SK microspheres 
presented similar biphasic configurations, consisting of an initial burst followed by a 
sustained release (Figure 4.7). CS modification reduced the initial burst so that CS-
Eud/SK microspheres had a longer sustained release phase when compared with those 
of Eud/SK microspheres. For instance, the cumulative releases of SK for Eud/SK and 
CS-Eud/SK microspheres were 41.4%, and 28.1% at 1 h and 99.3% and 88.6% at 5 h, 
respectively. Both mixtures of PEG/SK + Eud/SK and PEG/SK + CS-Eud/SK 
microspheres showed a faster release of the entrapped SK during the first 30 min 
followed by a continuous release for 5 h and 8 h, respectively. The SK release from 
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PEG/SK + CS-Eud/SK microspheres within the first 30 min was slightly lower than that 





Figure 4.7. In Vitro Release Study of SK from PEG/SK, Eud/SK and CS-Eud/SK 
































Figure 4.8. Fit of the Mathematical Models to the Experimentally Determined Release 
of SK from PEG/SK, Eud/SK and CS-Eud/SK Microspheres [YPEG/SK = 100(1 – e
−4.27t
); 
YEud/SK = 100(1 – e
−0.6t






The release rate constants (kx) and the correlation coefficients (R
2
) between the 
experimentally obtained and the fitted data calculated by the above-mentioned 
mathematical models appear in Table 4.3. Release data of PEG/SK and Eud/SK 
microspheres were found to fit first-order kinetics [YPEG/SK = 100(1 – e
−4.27t
); YEud/SK = 
100(1 – e
−0.6t
)] while release data for CS-Eud/SK fitted the Hixson-Crowell model   
[YCS-Eud/SK = 100(1 – (1 – 0.1t)
3
)]. Fit of the mathematical models to the experimentally 
determined release of SK from PEG/SK, Eud/SK and CS-Eud/SK microspheres are 





































Table 4.3. Release Rate Constants (kx) (mean ± standard error of the mean, n = 5) and 
Correlation Coefficients (R
2












-38.60 ± 13.34 -15.82 ± 2.79 -15.36 ± 4.37 
R
2





4.27 ± 0.90 0.60 ± 0.07 0.40 ± 0.01 
R
2





79.55 ± 14.65 35.63 ± 0.56 33.77 ± 0.45 
R
2





2.23 ± 0.51 0.55 ± 0.04 0.47 ± 0.01 
R
2
 0.7934 0.9692 0.9994 
a 




















Figure 4.9. In Vitro Release Study of SK from Mixtures of PEG/SK + Eud/SK 
Microspheres and PEG/SK + CS-Eud/SK Microspheres (The Dose Fractionation of SK 
Activity between PEG/SK and Eud/SK Microspheres or CS-Eud/SK Microspheres was 
1:5) (mean ± standard error of the mean, n=5). 
 
 
The morphological change of CS-Eud/SK microspheres in PBS pH 7.4 solution 
was investigated via SEM. After 2 h, swelling and loss of spherical shape of 
microspheres were observed (Figure 4.10). After 6 h, additional swelling could be seen. 









































Figure 4.10. SEM Images of CS-Eud/SK Microspheres after 2 h (A) and 6 h (B) in PBS 




4.3.2. In Vitro Thrombolytic Study 
At the beginning of the lysis experiments (0 h), the clot lysis times for PEG/SK 
+ Eud/SK and PEG/SK + CS-Eud/SK microspheres were significantly shorter than that 
of free SK + blank CS-Eud microspheres (Table 4.4). At the stage of the 2 h 
“reocclusion” lysis experiment, the clot lysis time for PEG/SK+CS-Eud/SK 
microspheres was reduced 19.7% when compared with that of PEG/SK + Eud/SK 
microspheres (27.7 ± 0.7 min vs. 34.5 ± 2.3 min, p<0.05). After 4 h, the clot lysis time 
for PEG/SK+ CS-Eud/SK microspheres was 38.4 ± 2.2 min. The PEG/SK + Eud/SK 
microspheres at 4 h, 6 h and the PEG/SK + CS-Eud/SK microspheres at 6 h showed no 
evidence of clot lysis after more than 60 min. Similarly, free SK + blank CS-Eud and 
PEG + free SK/blank CS-Eud microspheres showed no evidence of clot lysis at 2 h, 4 h 
and 6 h (Table 4.4). Thus, PEG/SK + CS-Eud/SK microspheres retain activity up to 4 h 
from beginning of the in vitro lysis experiment. 
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Table 4.4. The Clot Lysis Times (min) of Four Fibrinolytic Formulation Mixtures at 
Different Stages of the Lysis Experiment (The Dose Fractionation of SK Activity 
Between PEG/SK and Eud/SK Microspheres or CS-Eud/SK Microspheres was 1:5) 
(mean ± standard error of the mean, n = 5) 
 
Microsphere Mixtures  0 h  2 h  4 h  6 h 
Free SK (2500 IU) +              19.3 ± 0.9 _  _  _ 
Blank CS-Eud 
PEG/SK (2500 IU) +             13.4 ± 1.6 _  _             _ 
Free SK (12500 IU)/Blank  
CS-Eud 
PEG/SK (2500 IU) +              12.8 ± 1.1* 34.5 ± 2.3 _             _ 
Eud/SK (12500 IU)          
PEG/SK (2500 IU) +   14.3 ± 1.3* 27.7 ± 0.7
†
 38.4 ± 2.2 _ 
CS-Eud/SK (12500 IU) 
* = p<0.05 vs. Free SK + Blank CS-Eud 
† 




Submicron Eud microspheres with SK were successfully prepared by the double 
emulsion method and the surface of the microspheres modified with CS while retaining 
fibrinolytic activity. The EE (%) based on protein content or protein activity of Eud/SK 
microspheres was higher than that of CS-Eud/SK microspheres because some proteins 
on the surface of Eud/SK microspheres were dissolved in solution and washed away 
during coating process. This resulted in the lower EE (%) of CS-Eud/SK microspheres 
than that of Eud/SK microspheres. It is also possible that some SK activity was lost 
during the preparation process from exposure to organic solvent, heat with sonication 
and shear during vortexing. 
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As a biocompatible polymer, CS has been used elsewhere to coat tPA-magnetic 
nanoparticles (88) and tPA-PLGA nanoparticles (18, 132) for accelerating thrombolysis 
or imparting sustained delivery of urokinase and SK (22, 133). Our results indicate CS 
also contributes to the observed release properties as does Eud. Eud is soluble near 
neutral pH and commonly used for enteric coating in pharmaceutical industry (119). In 
medium pH 7.4, the dissolution of Eud starts with the diffusion of water and hydroxyl 
ion into the polymer matrices to form a gel layer and then the carboxylic acid groups are 
ionized, facilitating the dissolution of the polymer (134). The presence of CS affects 
this dissolution process. The pKa of the primary amine groups of CS is between 6.3 and 
7.0. Therefore, it is not soluble in PBS pH 7.4 (135) but it absorbs water and swells on 
contact with PBS pH 7.4. As the Eud interior of the microsphere dissolves, SK is 
released by desorption from Eud copolymer so that it can diffuse through the swollen 
CS layer. When CS is conjugated to the surface of Eud microspheres, it acts as a 
physical barrier to retard water and hydroxyl ion entering the microsphere matrix and to 
slow the diffusion of SK into the bulk solution. This led to a reduced initial ‘‘burst 
phase’’ and a slower ‘‘sustained release phase’’ of CS-Eud/SK microspheres compared 
with Eud/SK microspheres. The burst effect is undesirable for a controlled release 
system because it results from dissolution of an uncontrolled portion of protein or drug 
entrapped on the surface of microspheres when microparticles are immersed in solution. 
Due to the covalent bonding of CS on the surface, CS-Eud/SK microspheres exhibited a 
reduction in initial burst effect.  
To investigate the mechanism of release SK from CS-Eud/SK microspheres, 




C. On contact with PBS pH 7.4, the swelling of CS and the formation of a gel 
layer in the matrices led to the loss of spherical shape of CS-Eud/SK microspheres 
(Figure 4.10A). Dissociation of the carboxylic acid groups in the Eud/SK polymer 
caused the polymer to expand by charge-charge repulsion, which combined with CS 
swelling, resulted in the loss of compact structure and disintegration into small 
fragments (Figure 4.10B).  
Prior work had shown that a dosage of 2500 IU of SK was adequate to generate 
in vitro thrombolysis in a capillary tube (65). Therefore, we used an amount of PEG/SK 
microspheres containing 2500 IU of SK (approximately 50 mg) for rapid fibrinolysis. 
Based on mathematical fits for release rates from Eud/SK and CS-Eud/SK microspheres 
(Figure 4.8), the dose of entrapped SK in Eud/SK or CS-Eud/SK microspheres was 
determined as 12500 IU so that the content of SK released at each stage after 2 h, 4 h 
and 6 h was approximately 2500 IU for the digestion of the secondary blood clots. The 
dose fractionation of SK activity between PEG/SK and Eud/SK microspheres or CS-
Eud/SK microspheres was 1: 5 and the total dose of entrapped SK in the mixtures of 
PEG/SK + Eud/SK microspheres or the mixtures of PEG/SK + CS-Eud/SK 
microspheres was set at 15000 IU.  
At the beginning of the lysis experiment (0 h), although Eud/SK microspheres 
released SK faster than CS-Eud/SK microspheres (Figure 4.7) and the SK released from 
PEG/SK + Eud/SK microspheres was higher than that from PEG/SK + CS-Eud/SK 
microspheres (Figure 4.9), there was not a significant difference in the clot lysis times 
between the two mixtures. The shorter lysis times obtained at 0 h for both PEG/SK + 
Eud/SK and PEG/SK +CS-Eud/SK microspheres compared with free SK was attributed 
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to the presence of PEG/SK microparticles (65). With the application of pressure, the 
SK-encapsulated microspheres were transported into the clot by convection or 
permeation (129, 136) so that fibrinolysis proceeded within the clot as well as at the 
leading edge (65).  
After 2 h, 4 h and 6 h, only Eud/SK microspheres or CS-Eud/SK microspheres 
remain for the “reocclusion” experiments, because PEG/SK microspheres dissolved 
completely after 45 min. Comparison of the release rates (Figure 4.7) and lysis results 
(Table 4.4) at 2 h and 4 h reveals the unusual nature of thrombolysis with encapsulated 
PA. One generally expects the activity of an agent to be proportional to the amount 
released. However, the opposite is true for this system with activity corresponding to 
the amount of encapsulated agent remaining. CS-Eud/SK exhibits faster lysis even 
though SK releases more slowly. This results from distributed intraclot thrombolysis 
which occurs with encapsulated PAs. Microspheres penetrate and release inside the 
thrombus leading to the fibrinolytic reaction throughout the volume of the clot rather 
than being limited to its surface. With fluorophore-tagged, encapsulated PA, Leach 
proved the fibrinolytic reaction proceeded to create SK associated voids throughout the 
interior of a thrombus (65). In contrast, the reaction only took place at the leading edge 
of the thrombus with the free agent, consistent with the report by Blinc (137), Diamond 
(138), and others (139, 140). Encapsulation blocks adsorption of SK at the surface and 
allows penetration overcoming high affinity, high surface area and low flow strongly 
favor binding of SK at the leading edge. Beside the pressure-driven hydrodynamic 
forces facilitating microsphere penetration, we note the electrostatic force between the 
positive potentials of CS on the surface of CS-Eud/SK microspheres and negative 
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potentials of fibrin of the blood clot at pH of 7.4 as another mechanism driving the CS-
Eud/SK microspheres to associate with the matrix of the blood clot and release of SK 
therein (17, 18). At the 4 h stage, the clot lysis time of CS-Eud/SK microspheres was 
longest (38.4 ± 2.2 min) because by that time the SK available from CS-Eud/SK 
microspheres was gradually diminishing.  
In the in vitro lysis experiment, the presence of CS coating on the surface of 
Eud/SK microspheres induced a much slower release of SK up to 8 h which would 
seem to provide clot-lytic efficacy in prevention of second blockage up to 4 h. A 3-cm 
clot is a stringent test for reocclusion since a reservoir of circulating PA in the body 
would presumably act before the thrombus reached that length. The test however only 
provides a comparison of thrombolytic activity with the delayed released formulations 
and serves as evidence of a potential approach to address reocclusion.  
For clinical practice, after administration a mixture of PEG/SK + CS-Eud/SK 
microspheres for thrombolytic therapy, microspheres are envisioned to rapidly 
accumulate on thrombus surface and within the thrombus. Evidences from a number of 
studies in a different species indicate that encapsulated PA when released within 
minutes will break up the thrombus and restore flow faster than free PA. This study has 
demonstrated that longer release times leading to extended half-life in plasma can be 
expected to offer protection from reocclusion episodes. 
Finally, we note that while Eud is a pH-sensitive material and has been widely 
employed in pharmaceutical industry for controlled-release of drugs, it is not 
biodegradable and its fate in circulation is not known (141). Recently however, Eud 
nanoparticles have been locally infused to treat in-stent restenosis following 
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percutaneous transluminal coronary angioplasty in a swine model (142). It has also been 
used in vivo for arteriovenous malformation (143, 144) If Eud is not approved for 
intravenous administration, other materials that have both pH-sensitive and 
biodegradable properties could apply the principles reported herein. Knowledge of this 
study can provide the basis for improvement of therapies for heart attack and stroke. 
4.5. Conclusions 
In this study, CS was successfully conjugated to the surface of Eud/SK 
microspheres by covalent bonding. This led to CS-Eud/SK microspheres with a lower 
EE (%) based on protein content or protein activity, and a much slower release of SK 
when compared with those of Eud/SK microspheres. In vitro thrombolytic study 
showed that a mixture of PEG/SK and CS-Eud/SK microspheres could break up the 
blood clot rapidly while also providing clot-lytic efficacy for prevention of a second 









Chapter 5 - Modified Dextran/Heparin-Based Triggered Release 
Microspheres for Cardiovascular Delivery of Therapeutic Drugs Using 





5.1. Introduction  
Thrombolytic drugs [e.g. tissue-specific plasminogen activator (tPA), 
streptokinase, and urokinase] actively dissolve clots by inducing fibrinolytic activity. 
They convert the proenzyme plasminogen to the active enzyme plasmin, which in turn 
breaks up the fibrin clot. But thrombolytic therapy has a possible serious uncontrolled 
bleeding side effect due to non-specific and systemic activation of these agents (5). 
Moreover, thrombolytic agents have short half-lives which need to be used with the 
higher dosages in clinical therapeutics, leading to increased risk of bleeding 
complications. In fact, this side effect can occur in as many as 20% patients receiving 
plasminogen activators (18). Therefore, a drug delivery system that releases these 
agents in a triggerable manner is desirable to prolong their circulatory half-lives and 
protect these agents from inactivation by components in the circulatory system and 
antibodies. Systems offering an on-demand controlled release might enhance 
therapeutic efficacy and reduce systemic side effects of thrombolysis. While our interest 
in thrombolysis motivated this work, we note its potential for controlled delivery of 
other agents.  
                                                 
3
 This work has been submitted to Journal of Microencapsulation. 
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Various triggering mechanisms have been described for drug delivery systems 
including pH (145), temperature (146), light (147), ultrasound (148) and magnetic 
stimuli (149). Recently, a heparin (HP)/protamine-based prodrug system has been 
developed for the controlled delivery of tPA at the clot site (24, 25). In this approach, 
cation-modified tPA was attached to a HP-antifibrin complex via ionic attraction. 
Protamine, a competitive HP inhibitor, was used as a triggering agent to release the 
active tPA from the prodrug for clot dissolution. Similarly, a HP/protamine-based 
system has been applied for delivery of the anticancer agents (150). Based on the 
electrostatic interactions between HP and ammonium moieties in modified dextrans, we 
offer a new triggerable drug delivery system in which a drug agent is physically 
entrapped inside microspheres formed by the double emulsion method (151).  This 
offers promise in extending prior work with HP/protamine to the delivery of a wide 
range of species without requiring chemical modification of the agent. 
Dextran is a biocompatible and biodegradable natural polymer that has been 
widely used in drug delivery systems. Owing to having many hydroxyl groups, dextran 
can easily be modified to meet various biomedical applications (94). Of which, cationic 
dextran polymers have been synthesized (Figure 5.1) by grafting amine-containing 
species to the backbone of dextran using reductive amination (152-155). To facilitate 
formation of the microparticles with the double emulsion method, some hydroxyl 
groups of dextran have been converted to hydrophobic structures yielding an 
intermediate acetalated dextran (DAC) (99, 108, 156). 
In this study, we describe the synthesis of a new amine-modified acetalated 
dextran polymer which is combined with HP to develop triggered release microspheres. 
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Amine groups, present as positively charged ammonium ions, will bind with the 
negatively charged HP. Protamine is then used as a triggering stimulus to release crystal 
violet (CV), a model drug, from these microspheres. We also investigate the effects of 
various factors such as the degree of amination and concentration of protamine on the 
release of CV from microspheres. 
5.2. Materials and Methods 
5.2.1. Materials 
Dextran from Leuconostoc spp. (average molecular weight: 70 kDa), poly(vinyl 
alcohol) (PVA, 87–90% hydrolyzed, average molecular weight: 30–70 kDa), dimethyl 
sulfoxide (DMSO), chloroform, sodium periodate, 2-methoxypropene, ethylendiamine, 
protamine sulfate salt from salmon, pyridinium p-toluenesulfonate sodium, 2,4,6-
trinitrobenzenesulfonic acid (TNBS), CV (molecular weight: 407.9 g/mol) were 
purchased from Sigma-Aldrich (St. Louis, MO). HP sodium was purchased from Fisher 
Scientific (Pittsburgh, PA). 
5.2.2. Synthesis of Dextran-Amine (DEXAM) Conjugates 
5.2.2.1. Oxidation of Dextran 
Dextran (3.0 g) was dissolved in 30 mL water. To this solution was separately 
added potassium periodate (0.8 g or 1.2 g), and the mixture was vigorously stirred for 6 
h in the dark at room temperature. The product was purified by dialysis of the solution 
against distilled water using a regenerated cellulose membrane with a MWCO of 3500 
g/mol (Fisherbrand, Fisher Scientific) for 48 h. Then, the sample was lyophilized for 24 
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h to obtain a white powder. The obtained products were designated as DO1 or DO2, 
respectively (154). 
5.2.2.2. Acetalation of Oxidized Dextran 
DO1 (2 g) was dissolved in 40 mL of DMSO at 90
o
C under nitrogen gas. After 
complete dissolution, the mixture was cooled down to room temperature and pyridinium 
p-toluenesulfonate (0.186 g) was added followed by 2-methoxypropene (14.4 mL) to 
the reaction vessel. The reaction continued at room temperature for 6 h under nitrogen 
gas and was quenched with triethylamine (1 mL). Product isolation followed from 
precipitation in distilled water, centrifugation (1000 × g for 5 min), removal of the 
supernatant, and washing several times with distilled water before lyophilizing for 24 h. 
The obtained product was designated as DAC1 (99, 108). 
DO2 (2 g) was reacted similarly with 2-methoxypropene (14.4 mL or 7.2 mL) 
yielding products which were designated as DAC2 or DAC3, respectively. 
5.2.2.3. DEXAM Conjugates 
Modified dextran of 2 g (DAC1, DAC2 or DAC3) was dissolved in 60 mL of 
DMSO at 90
o
C under nitrogen gas. After complete dissolution, the mixture was cooled 
down to room temperature. Ethylendiamine (8 mL) was added and stirred for 22 h at 
room temperature. Then, sodium borohydride (2.0 g) was added to the reaction vessel 
and stirred for 24 h at room temperature. The product was precipitated in distilled water 
and was isolated by centrifugation at 1000 × g for 5 min, and then was washed with 
distilled water, followed by centrifugation and removal of the supernatant before 
lyophilizing for 24 h. The obtained products were designated as DEXAM1, DEXAM2, 
and DEXAM3, respectively (154, 155). 
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5.2.3. Characterization of DEXAM Conjugates 
5.2.3.1. Determination of Degree of Oxidation 
Degree of oxidation was determined according to the literature (154, 157). In 
brief, aqueous DO1and DO2 solutions (0.1 mg/mL) were prepared and absorbances of 
samples were measured at 562 nm with a plate reader (Synergy HT plate reader, Bio-
Tek) using a microplate reductometric bicinchoninic acid assay (Micro BCA, Protein 
Assay Kit, Pierce). An aqueous dextran solution (0.1 mg/mL) was used as a blank in the 
absorbance measurements. The degree of oxidation (the aldehyde content) was 
calculated according to the calibration curve formed from the absorbances of a series of 
glucose solutions (0.01, 0.025, 0.05, 0.075, 0.1 mg/mL). 
5.2.3.2. Determination of Degree of Acetalation by the NMR Method 
The acetal content was determined by NMR analysis as described in the 
literature (99). In brief, DAC was suspended in deuterium oxide and hydrolyzed with 
deuterium chloride. Then, the NMR spectra of DAC were recorded (Varian VNMRS 
400 MHz NMR Spectrometer). Based on the integration of reference NMR signals for 
acetone and methanol at 2.1 and 3.3 ppm, respectively, the content of acetal groups was 
calculated. 
5.2.3.3. Determination of Primary Amines by the TNBS Method 
The primary amine content was determined as described previously (153). In 
brief, DEXAM (10 mg) was dissolved in 10 mL pH 4.0 acetate. 20 µL of freshly 
prepared aqueous TNBS solution (15 mg/mL) was added to 600 µL of this solution, 
followed by adding 200 µL of pH8.5 sodium bicarbonate buffer, vortexed for 1 min, 
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and incubated for 2 h at 37
o
C. Then, 600 µL of 1 N HCl solution was added, vortexed 
for 1 min, and gently sonicated for 2 min to remove bubbles. Absorbances of samples 
were measured spectrophotometrically at 410 nm (Shimadzu UV-2450). A sample of 
dextran was used as a blank in the absorbance measurements. The primary amine 
content was calculated according to the calibration curve of ethylenediamine. 
5.2.3.4. Fourier Transform Infrared (FT-IR) Spectroscopy 
Infrared spectra were obtained by Nicolet 6700 FT-IR Spectrometer. Dried 
samples were ground with KBr powder, and pressed into pellets for FT-IR examination. 
5.2.4. Development and Characterization of Microspheres  
5.2.4.1. Preparation of Microspheres by W/O/W Double Emulsion Method 
Microspheres were prepared by a double emulsion method (124). Briefly, HP 
sodium and CV (5 mg) was dissolved in 0.6 mL distilled water. DEXAM conjugates 
(0.3 g) were dissolved separately in 3 mL of chloroform. The two solutions were mixed 
for 30 s and sonicated at 45 W for 1 min using a sonicator (Sonic Dismembrator 60, 
Fisher Scientific). The primary emulsion was mixed with 6 mL of PVA 3% (w/v), 
sonicated for 30 s to produce W/O/W emulsion. Then, 50 mL of PVA 0.3% (w/v) was 
added to the emulsion. The suspension was mechanically stirred at 1200 rpm for 3 h at 
room temperature to remove the organic solvent. The microspheres were isolated by 
centrifugation (1000 × g for 10 min) and washed with distilled water by vortexing for 
30 s and then centrifuging several times to remove the residual PVA and solvent. The 
washed microspheres were suspended in distilled water (1 mL) and lyophilized for 20 h. 
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In separate runs, the amount of HP sodium was a 1/3 or 1/2 mass ratio of the 
amount of dextran-amine conjugates. These microspheres were designated as 
DEXAM/HP1/3 and DEXAM/HP1/2, respectively. 
5.2.4.2. Drug Encapsulation Efficiency 
CV microspheres of 10 mg were allowed to dissolve completely in 10 mL pH 
4.0 acetate buffer for 12 h. The content of entrapped CV in the microspheres was 
determined spectrophotometrically (Shimadzu UV-2450) at 590 nm (158). 
Encapsulation efficiency (EE) (%) was calculated using the following equation: 
 
𝐸𝐸(%) =




5.2.4.3. Particle Size  
Particle diameter was determined using a laser diffraction particle size analyzer 
(Beckman Coulter LS230). Particle size measurements are based on diffraction patterns 
formed by the scattering of light by microparticles. Particle sizes were obtained and 
analyzed using the accompanying software of the instrument. 
5.2.4.4. In Vitro CV Release Study 
Microspheres (25 mg) were dispersed in 10 mL of phosphate-buffered saline 
solution (PBS 10 mM, pH 7.4) in test tubes. Protamine sulfate was added to test tubes to 
make 0.1%, 0.25% or 0.5% solution. The test tubes were placed in an orbital shaker at 
37
o
C and agitated at 80 rpm. At specific time points, 2 mL of solution was drawn and 
filtered for testing. 2 mL of 0.1%, 0.25% or 0.5% protamine in PBS 10 mM, pH 7.4 was 
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replenished to maintain a constant sink volume. The CV release rate was continuously 
measured with spectrophotometer (Shimadzu UV-2450) at 590 nm. 
5.2.4.5. SEM Images 
To assess the mechanism of CV release from DEXAM/HP microspheres, the 
morphological change of microspheres in 0.5% protamine /PBS pH 7.4 was monitored 
with SEM (Zeiss NEON 40 EsB). DEXAM2/HP1/2 microspheres (20 mg) were 
dispersed in 10 mL 0.5% protamine /PBS pH 7.4 at 37
o
C. After 15 min, 1 h, 2 h, 4 h, 6 
h and 12 h, samples were collected by centrifuge at 1000 × g for 10 min and then 
lyophilized for 15–20 h. A small amount of freeze-dried microspheres was loaded on an 
aluminum stub with double-sided adhesive tape. Samples were sputter coated with gold 
and examined by SEM at 15 kV. 
5.2.5. Statistical Analysis 
Unless otherwise stated, all data are presented as mean ± standard error of the 
mean. Student’s t-test was used to determine significance between two groups. P-values 
less than 0.05 were considered significant. 
5.3. Results 
5.3.1. Characterization of DEXAM Conjugates 
DEXAM conjugates were synthesized by using the reductive amination reaction 
method to graft ethylenediamine to the backbone of the modified dextran that had been 
previously acetalated (Figure 5.1). First, dextran was oxidized using sodium periodate 
to obtain the dialdehyde derivative. Second, this derivative was acetalated to transform 
water-soluble dextran into a hydrophobic polymer which was suitable for preparation of 
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microspheres by the double emulsion method. Finally, the acetalated dialdehyde 
polymer was reacted with ethylendiamine and reduced by borohydride to form DEXAM 
conjugates. 
The product was characterized by FT-IR (Figure 5.2) with the spectrum of DAC 
showing peaks of acetal groups at 2989, 1386, and 1239 cm
-1
, consistent with a 











Figure 5.2. FT-IR spectra of (A) Dextran, (B) DAC and (C) DEXAM Conjugates. 
 
 
The degree of oxidation, degree of acetalation and the primary amine content are 
presented in Table 5.1. Increasing the amount of sodium periodate in the oxidation 
reaction of dextran (0.8 to 1.2 g) resulted in a greater degree of oxidation from 9.8 ± 
0.15 mol aldehyde /100 mol anhydroglucose unit (AGU) of DO1 to 12.7 ± 0.44 mol 
aldehyde /100 mol AGU of DO2 (p<0.05). This led to increasing the primary amine 
content from 7.4 ± 0.3 mol primary amine/100 mol AGU of DEXAM1 to 9.9 ± 0.2 and 
10.1 ± 0.2 mol primary amine/100 mol AGU of DEXAM2 and DEXAM3, respectively, 
(p<0.05) which indicated the amount of ethylenediamine grafted on the dextran 




Table 5.1. Characterization of the Modified Dextran (mean ± standard error of the 
mean, n = 6) 




Degree of Acetalation 
(mol acetalated 
hydroxyls /100 mol 
AGU)
b 




DEXAM1 9.8 ± 0.15 188.9 ± 3.3 7.4 ± 0.3 
DEXAM2 12.7 ± 0.44* 178.8 ± 3.4 9.9 ± 0.2
‡
 
DEXAM3 12.7 ± 0.44* 159.6 ± 2.8
†
 10.1 ± 0.2
‡ 
a
 Degree of oxidation in DO derivatives; * = p<0.05 vs. DO1 
b
 Degree of acetalation in DAC derivatives; 
† 
= p<0.05 vs. DAC2 
‡ 




In contrast, increasing the degree of oxidation led to slight drop in the degree of 
acetalation from 188.9 ± 3.3 mol acetalated hydroxyls/100 mol AGU of DAC1 (63.0% 
of the available hydroxyl groups was modified) to 178.8 ± 3.4 mol acetalated 
hydroxyls/100 mol AGU of DAC2 indicating that 59.6% of the available hydroxyl 
groups were modified. Decreasing the amount of 2-methoxypropene from 14.4 mL to 
7.2 mL in the acetalation reaction of DO2 resulted in decreasing the acetal content of 
DAC [178.8 ± 3.4 vs.159.6 ± 2.8 mol acetalated hydroxyls/100 mol AGU (53.2% of the 
available hydroxyl groups was modified), p<0.05)]. Due to the presence of acetal 
groups, the obtained DEXAM1, DEXAM2 and DEXAM3 are insoluble in aqueous 
media. 
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5.3.2. Development and Characterization of DEXAM/HP Microspheres 
As shown in Table 5.2, the particle size of DEXAM/HP microspheres was 1.2 - 
1.6 µm in diameter, varying with the primary amine content of DEXAM. Moreover, 
when the amount of HP for preparation of DEXAM2/HP microspheres was reduced, the 
size of the obtained microspheres was found to decrease. The mean particle diameter of 
DEXAM2/HP1/3 microspheres was smaller than that of DEXAM2/HP1/2 microspheres 
(1.247 ± 0.027 µm vs.1.563 ± 0.026 µm, p<0.05). 
 
Table 5.2. Characterization of DEXAM/HP Microspheres (mean ± standard error of the 
mean, n = 6) 
Microspheres Mass Ratio
a
 Particle Size (µm) EE (%) 
DEXAM1/HP1/2 1: 1/2 1.367 ± 0.018 78.4 ± 2.6 




DEXAM3/HP1/2 1: 1/2 1.607 ± 0.044*
 
91.0 ± 2.5* 
DEXAM2/HP1/3 1: 1/3 1.247 ± 0.027 79.1 ± 1.8 
a
 DEXAM: HP 
* = p<0.05 vs. DEXAM1/HP1/2 
† 
= p<0.05 vs. DEXAM2/HP1/3 
 
 
EE (%) of DEXAM/HP microspheres was found to depend on the primary 
amine content and the amount of HP for preparation of DEXAM/HP microspheres 
(Table 5.2). The EE (%)  increased from 78.4 ± 2.6% to 91.0 ± 2.5% as the primary 
amine content of DEXAM rose from 7.4 ± 0.3 to 10.1 ± 0.2 mol primary amine/100 mol 
AGU. The EE (%) of DEXAM2/HP microspheres was decreased when the amount of 
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HP for preparation of DEXAM2/HP microspheres was reduced (89.6 ± 2.0% of 
DEXAM2/HP1/2 microspheres vs. 79.1 ± 1.8% of DEXAM2/HP1/3 microspheres, 
p<0.05). 
5.3.2.1. In Vitro CV Release Study 
We investigated the effect of variables such as chemical properties of DEXAM 
polymer, mass ratios between DEXAM and HP, and concentrations of protamine on the 
release profile of CV. It was observed that protamine accelerated the release of CV 
(Figure 5.3) which was negligible in its absence. The release of CV from 
DEXAM2/HP1/2 microspheres was increased from 27.6% to 59.1% at 4 h when the 
concentration of protamine was changed from 0.1% to 0.5%. The percentage released 
was based on the amount of CV released with time over the actual amount of CV 
encapsulated in microspheres. 
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Figure 5.3. In Vitro Release of CV from DEXAM2/HP1/2 Microspheres with Time as a 




Figure 5.4. In Vitro Release of CV from DEXAM/HP Microspheres with Time as 
Functions of the Primary Amine Content or the Amount of HP with a Fixed 






































































The release profile of CV from DEXAM/HP microspheres was also dependent 
on the primary amine content and the amount of HP when suspended in a fixed 
concentration of protamine (0.5%) (Figure 5.4). Increasing the primary amine content of 
DEXAM (DEXAM1/HP1/2, DEXAM2/HP1/2, DEXAM3/HP1/2 microspheres) or the 
amount of HP when preparation of microspheres (DEXAM2/HP1/2, DEXAM2/HP1/3 
microspheres) resulted in accelerating of CV release. DEXAM3/HP1/2 microspheres 
released 62.4% of entrapped CV after 4 h. In contrast, DEXAM1/HP1/2 microspheres 
released only 43% of entrapped CV after 5 h. 
5.3.2.2. SEM Images 
SEM images demonstrated that the shapes of DEXAM/HP microspheres were 
spherical with a fairly smooth particle surface (Figure 5.5). Particle size of 
approximately 1.5 µm by SEM confirms findings by light scattering.  
 
 
Figure 5.5. SEM Image of DEXAM/HP Microspheres. 
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To understand the mechanism of CV release from microspheres, the 
morphological change of DEXAM2/HP1/2 microspheres in 0.5% protamine /PBS pH 
7.4 was monitored by SEM (Figure 5.6). The SEM images showed that protamine 
bound to the surface of microspheres after 15 min (Figure 5.6A). Then, the surface of 
microspheres becomes rough with pores gradually appearing on the surface of 
microspheres after 1 h (Figure 5.6B). Next,  more cracks and pores can be seen on the 
surface at 2 h  while only remnants of an outer coating is visible at 4 h (Figure 5.6C and 


























Figure 5.6. SEM Images of DEXAM2/HP1/2 Microspheres in 0.5 % Protamine /PBS 




HP is a highly sulfated glycosaminoglycan and has negative charges under 
physiologic conditions (160). Its use as an anticoagulant is well known (161). 
Protamine, a positively charged protein, forms a complex with HP by electrostatic 
interactions. Protamine binds strongly to HP, displaces typical gegenions, and inhibits 
its mode of action (162). Protamine sulfate has been widely utilized clinically to reverse 
heparin-induced anticoagulation (163, 164). In clinical practice, the dose of protamine is 
determined by the HP exposure: 1 mg of protamine sulfate neutralises 80-100 IU of HP 
(165). The lethal dose (LD50) of protamine sulfate is 100 mg/kg in mice (166). In this 
study, we used protamine sulfate with concentrations ranged from 0.1% to 0.5% (w/v) 
to determine whether or not protamine would trigger the release of CV from 
DEXAM/HP microspheres.  
Based on the electrostatic interactions of HP with cationic polymers, other drug 
delivery systems have been developed for biomedical applications (167-169). In this 
study, we investigated a triggerable drug delivery system incorporating the 
biodegradable and biocompatible polymer dextran. CV was encapsulated inside 
DEXAM/HP microspheres via packing by the emulsion process and the electrostatic 
bindings between DEXAM conjugates and HP.  
In this study, we did not use bovine serum albumin (BSA) as a model protein 
because when determining the amount of BSA encapsulated in DEXAM/HP 
microspheres by bicinchoninic acid (BCA) method, the aldehyde groups of DEXAM 
conjugates also reacted with BCA reagents, leading to inaccurate results. This reaction 
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is used to determine the degree of oxidation (the aldehyde content) of DEXAM 
conjugate (see 5.2.3.1). Instead, we use CV as a model drug. 
DEXAM conjugates were synthesized using the reductive amination reaction 
method (Figure 5.1). Acetal groups of DEXAM conjugates help to transform water-
soluble dextran into a hydrophobic polymer. We found the primary amine content 
affects the characteristics of DEXAM/HP microspheres because the positive charges of 
DEXAM interacted with the negative charges of HP, contributing to the structural 
integrity of the microspheres. The higher primary amine content, the more HP and 
DEXAM aggregated in the microspheres, leading to increase the particle size.  
CV is a triaminotriphenylmethane dye with a cationic tertiary amine group (170) 
which allows CV to interact and form complexes with negatively charged HP in the 
internal water phase as they were encapsulated in the modified dextran microparticles. 
Thus, the larger amount of HP was entrapped, the higher EE (%) of DEXAM/HP 
microspheres. 
The same trend was observed when increasing the amount of HP resulted in an 
increase the particle size and EE (%) of DEXAM/HP microspheres with a fixed content 
of the primary amine (DEXAM2/HP1/2 and DEXAM2/HP1/3 microspheres). In fact, in 
the fabrication process of microspheres, a high HP concentration in the internal water 
phase enhanced the viscosity of primary emulsion, which reduced the efficiency of 
mixing and formation of larger emulsion droplets (171, 172). The interaction between 
DEXAM conjugates and HP at the O-W interface during the double emulsion process 
seemed to form an outer shell of microspheres which can be observed in Figure 6C and 
6D. The size of microspheres increases with the amount of DEXAM or HP because 
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more complexes form at the interface. Therefore, the higher amount of HP led to the 
larger microparticles. 
Electrostatic interactions of DEXAM conjugates, HP, and protamine help to 
explain the mechanism of CV release from microspheres that was monitored via SEM 
images. In the absence of protamine, the microspheres are fairly stable with 
approximately 5% of CV released after 12 h in PBS pH 7.4. This CV release is 
attributed to the diffusion of CV or HP on the surface of microspheres into medium. 
When protamine was present, HP on the surface of the microspheres gradually binds to 
protamine and dissociates from DEXAM with degradation of the microspheres. HP/ 
protamine might be dissolved into the surround medium. During this process, there is a 
competition between protamine and DEXAM conjugates to bind with HP. As HP 
disaggregates, the outer shell of microspheres is eroding, leading to the appearance of 
pores on the surface of microspheres (Figure 5.6C and 5.6D). Water and protamine 
continue to penetrate microspheres, resulting in the disaggregation and dissolution of 
HP lodged inside microspheres and accelerating CV release. When HP is completely 
disaggregated, the remnant of microspheres appears (Figure 5.6E and 5.6F). This 
remnant is DEXAM conjugates which is not degradable in pH 7.4 medium due to the 
acetal groups (108) . The DEXAM/HP microspheres do not completely release their CV 
payloads because more than 30% of CV is still entrapped inside these remaining cores 
The release rate of CV depended on the disaggregation rate of HP from 
microspheres due to interact with protamine. So that when we changed the 
concentration of protamine, the disaggregation rate of HP changed accordingly, leading 
to changing of the release rate of CV. The release rate of CV also depended on the 
98 
primary amine content of DEXAM conjugates. The higher primary amine content, the 
larger amount of HP aggregated in microspheres, leads to the more HP disaggregate 
from microspheres when suspended in a fix concentration of PS. 
To improve the cumulative amount of CV released from microspheres, we can 
enhance the primary amine content of DEXAM conjugates by using dextran with low 
molecular weight because oxidized dextran with lower molecular weight (9.3-40 kDa) 
may resulted in higher aldehyde content and therefore in a higher the primary amine 
content (152, 153). 
5.5. Conclusions  
In this study, DEXAM conjugates with various primary amine contents were 
successfully synthesized by the reductive amination reaction method in an effort to be 
combined with HP to develop the triggered release microspheres using protamine as a 
triggering agent. The primary amine contents and amount of HP affected the 
characteristics of the DEXAM/HP microspheres. In addition, protamine triggered the 
release of CV from DEXAM/HP microspheres. Future studies using dextran with lower 













The overall goal of this research was the design, synthesis, characterization and 
testing of microspheres which i) are suitable for extension the half-life of SK for 
prevention of reocclusion in vitro, and ii) provide a general controlled release by 
triggered release mechanism for cardiovascular delivery of therapeutic drugs. This 
chapter summarizes the concluding remarks of this work and the knowledge gained 
from the previous chapters. 
6.1.1. Summaries from Chapter 3 
 DA with various degrees of substitution was successfully synthesized by the 
reaction of dextran with acetic anhydride.  
 A series of PEG/DAs microspheres were prepared by a modified double emulsion 
method and tested with BSA functioning as a model protein.  
 Increasing the degree of substitution of DA resulted in slower release of BSA from 
PEG/DAs microspheres  
 PEG/DA3 microspheres provided the release of BSA on the scale of hours (180 
min) 
 The percentage of BSA released from PEG and PEG/DA3 microspheres with time 
(min) was modeled mathematically [YPEG = 100(1 –e
−0.12t




)] in order to predict cumulative delivery from mixtures in vitro over a period 
of hours when constrained to a target level at 30 min.   
6.1.2. Summaries from Chapter 4 
 CS was successfully conjugated to the surface of Eud/SK microspheres by covalent 
bonding.  
 With CS coating on the surface, CS-Eud/SK microspheres exhibited a lower EE (%) 
based on protein content or SK activity and a much slower release of SK up to 8 h 
when compared with those of Eud/SK microspheres.  
 In vitro lysis experiment: mixture of PEG + CS-Eud/SK microspheres could break 
up the blood clot rapidly while also provide clot-lytic efficacy for prevention of 
second blockage up to 4 h.  
 Counter-intuitively, slower release of SK from CS-Eud/SK microspheres led to 
faster thrombolysis as a result of greater penetration of agent into the thrombus and 
the mechanism of distributed intraclot thrombolysis.  
6.1.3. Summaries from Chapter 5 
 DEXAM conjugates were successfully synthesized using reductive amination 
reaction.  
 HP bound to positively charged ammonium ions of the DEXAM conjugates, 
contributing to the structural integrity of the microspheres.  
 Binding of protamine to HP creates conformational changes leading to mechanical 
stresses and release of the encapsulated CV.  
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 Release of CV from microspheres varied with primary amine content of DEXAM 
conjugates, amount of HP, and concentration of protamine added.  
6.2. Future Work 
Based on this work and the design of thrombolytic formulations for rapid 
reperfusion and prevention of another blockage, several important research steps can be 
pursued in the near future.  
Following our current work on testing the thrombolytic formulations on 
dissolving plasma blood clot in vitro (Chapter 4), the future work needs to test the 
pharmacokinetic profile and thrombolytic efficacy of the formulation mixture of 
PEG/SK + CS-Eud/SK microspheres in animal models. 
We have designed a general controlled release drug delivery system based on 
protamine induced degradation DEXAM/HP microspheres (Chapter 5). Binding 
constants for the interaction between DEXAM conjugates and HP, and between 
protamine and HP need to be determined to characterize the competitive binding 
between DEXAM conjugates and protamine to HP. In addition, we have shown that 
increasing the primary amine content of DEXAM conjugate results in increasing the CV 
release from DEXAM/HP microspheres. Therefore, as further steps of the project, we 
hypothesize that using dextran with lower molecular weight (9.3-40 kDa) in the 
reductive amination reactions for synthesis of DEXAM conjugates can improve the CV 
release from microspheres because the lower molecular weight of dextran used results 
in the higher primary content  of DEXAM conjugates. With the higher amine content of 
DEXAM conjugates, we can attach ligands, such as anti-fibrin antibody, to the surface 
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